المؤلفون: O. N. Egorova, G. M. Tarasova, B. G. Issaeva, A. V. Datsina, D. S. Dilmanova, S. M. Issaeva, M. G. Nogaeva, A. G. Issaeva, A. S. Amanzholova, M. M. Saparbayeva, A. A. Atasheva, A. B. Kanapina, О. Н. Егорова, Г. М. Тарасова, Б. Г. Исаева, А. В. Дацина, Д. С. Дильманова, С. М. Исаева, М. Г. Ногаева, А. Г. Исаева, А. С. Аманжолова, М. М. Сапарбаева, А. А. Аташева, А. Б. Канапина

المساهمون: Статья подготовлена в рамках научно-исследовательской работы (№/№ государственных заданий РК 122040400024-7) и международного научного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) с Казахским Национальный Медицинским Университетом им. С.Д. Асфендиярова (Казахстан).

المصدر: Modern Rheumatology Journal; Том 18, № 2 (2024); 7–15 ; Современная ревматология; Том 18, № 2 (2024); 7–15 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: лекарственные средства, diagnostics, rheumatic diseases, idiopathic lung diseases, malignant diseases, autoimmune liver pathology, drugs, диагностика, ревматические заболевания, идиопатические заболевания легких, онкологические заболевания, аутоиммунная патология печени

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1556/1452; Van Beers JJBC, Vanderlocht J, Roozendaal C, Damoiseaux J. Detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence. Methods Mol Biol. 2019:1901:47-62. doi:10.1007/978-14939-8949-2_4.; Csernok EJ, Damoiseaux N, Hellmich RB,et al. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev. 2016 Jul;15(7):736-41. doi:10.1016/j.autrev.2016.03.010. Epub 2016 Mar 9.; Mukhtyar C, Flossmann O, Hellmich B, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008 Jul;67(7):1004-10. doi:10.1136/ard.2007.071936. Epub 2007 Oct 2; Ou CC, Wu YC, Chen JP, et al. Association of atypical anti-neutrophil cytoplasmic antibody with comorbidities and outcome in a hospital-based population. Heliyon. 2024 Jan 6;10(1):e24105. doi:10.1016/j.heliyon.2024.e24105.; Moiseev S, Cohen Tervaert JW, Arimura Y,et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020 Sep;19(9):102618. doi:10.1016/j.autrev.2020.102618. Epub 2020 Jul 12.; Li W, Chen R, Chen W, et al. Clinicopathological Features and Outcomes of IgA Nephro pathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity. Am J Nephrol. 2023; 54(9-10):416-424. doi:10.1159/000533982. Epub 2023 Sep 19.; Xiong Q, Lin W, Shen C, et al. Coexistence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and IgA nephropathy. Immunol Res. 2023 Feb; 71(1):1-14. doi:10.1007/s12026-022-09322-8.; Sato N, Yokoi H, Imamaki H, et al. Renallimited vasculitis with elevated levels of multiple antibodies. CEN Case Rep. 2017 May; 6(1):79-84 doi:10.1007/s13730-017-0248-3. Epub 2017 Mar 3.; Palha V, Sa A, Pimentel T, et al. A rare caseof pulmonary-renal syndrome with triple-seropositive for myeloperoxidase-anti-neutrophil cytoplasm antibody (MPO-ANCA), proteinase 3 (PR3)-ANCA and anti-glomerular basement membrane (GBM) antibodies. J Med Cases. 2021 Oct;12(10):405-410. doi:10.14740/jmc3742.; Olson SW, Arbogast CB, Baker TP, et al.Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol. 2011 Oct;22(10): 1946-52. doi:10.1681/ASN.2010090928. Epub 2011 Aug 25.; Matsuno S, Itabashi M, Komatsu A, et al.Anti-glomerular basement membrane disease developing 3 years after the development of Sweet syndrome and 1 year after the development of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. CEN Case Rep. 2023 Aug;12(3):259-264. doi:10.1007/s13730-022-00758-3.; Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Anti-Glomerular Basement Membrane Antibody-Mediated Glomerulonephritis. Am J Kidney Dis. 2016 Nov;68(5):e29-e30. doi:10.1053/j.ajkd.2016.09.003.; Zhao J, Yang R, Cui Z, et al. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract. 2007;107(2):c56-62. doi:10.1159/000107803.; McAdoo SP, Pusey CD. Antiglomerularbasement membrane disease. Semin Respir Crit Care Med. 2018 Aug;39(4):494-503. doi:10.1055/s-0038-1669413.; McAdoo SP, Tanna A, Hruskova Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017 Sep;92(3):693-702. doi:10.1016/j.kint.2017.03.014.; Van Daalen EE, Jennette JC, McAdoo SP,et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):63-72. doi:10.2215/CJN.04290417.; Segelmark M, Hellmark T. Anti-glomerular basement membrane disease: an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant. 2019 Nov 1;34(11):1826-1832. doi:10.1093/ndt/gfy327.; Levy JB, Hammad T, Couthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004 Oct;66(4):1535-40. doi:10.1111/j.1523-1755.2004.00917.x.; Gluhovschi C, Gadalean F, Velciov S, et al. Three Diseases Mediated by Different Immunopathologic Mechanisms-ANCA-Associated Vasculitis, Anti-Glomerular Basement Membrane Disease, and Immune Complex-Mediated Glomerulonephritis-A Common Clinical and Histopathologic Picture: Rapidly Progressive Crescentic Glomerulonephritis. Biomedicines. 2023 Nov 6;11(11): 2978. doi:10.3390/biomedicines11112978.; Rutgers A, Slot M, van Passen P, et al.Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidaseANCAs in crescentic glomerulonephritis. Am. Kidney Dis. 2005 Aug;46(2):253-62. doi:10.1053/j.ajkd.2005.05.003.; Sadeghi-Alavijeh O, Henderson S, Bass P,et al. Crescentic glomerulonephritis with antiGBM antibody but no glomerular deposition. BMC Nephrol. 2018 Sep 12;19(1):228. doi:10.1186/s12882-018-1027-x.; Petri М, Orbai AM, Alarcуn GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2012 Aug;64(8): 2677-86. doi:10.1002/art.34473.; Tervaert JW, Mulder AH, Kallenberg CG. Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA): clinical significance and relation to antibodies against myeloid lysosomal enzymes. Adv Exp Med Biol. 1993:336: 253-6. doi:10.1007/978-1-4757-9182-2_37.; Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am. J. Nephrol. 2000 Jan-Feb;20(1):57-63. doi:10.1159/000013557.; Wang Y, Yu Х, Xie Х, et al. Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus. Ren Fail. 2023 Dec; 45(1):2235431. doi:10.1080/0886022X.2023.2235431.; Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651-8. doi:10.1191/0961203303lu456rr.; Pan Y, He L. Perinuclear anti-neutrophilcytoplasmic antibody in systemic lupus erythematosus indicates more severe condition. Clin Biochem. 2021 Mar: 89:38-43. doi:10.1016/j.clinbiochem.2020.12.004; Yu F, Tan Y, Liu G, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009 Aug;76(3):307-17. doi:10.1038/ki.2009.136. Epub 2009 Apr 29.; Olson SW, Lee JJ, Poirier M, et al. Antimyeloperoxidase antibodies aassociate with future proliferative lupus nephritis. Autoimmune Dis. 2017:2017:1872846. doi:10.1155/2017/1872846. Epub 2017 Dec 24.; Schnabel А, Csernok Е, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis Rheum. 1995 May;38(5):633-7. doi:10.1002/art.1780380509.; Galeazzi M, Morozzi G, Sebastiani GD,et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998 Sep-Oct;16(5):541-6.; Gajic-Veljic М, Lekic В, Nikolic М. Level and avidity of antineutrophil cytoplasmic antibodies specific to lactoferrin are useful biomarkers in systemic lupus erythematosus. Clin Rheumatol. 2022 Mar;41(3):709-720. doi:10.1007/s10067-021-05926-x. Epub 2021 Oct 7.; Frangou E, Vassilopoulos D, Boletis J,Boumpas DT. Аn emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev. 2019 Aug;18(8):751760. doi:10.1016/j.autrev.2019.06.011.; Brilland B, Garnier AS, Chevailler A, et al. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmun Rev. 2020 Jan;19(1):102424. doi:10.1016/j.autrev.2019.102424.; Senda А, Sasai R, Kato K, et al. Involvement of neutrophil extracellular traps in the pathogenesis of glomerulonephritis in a case of systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome. CEN Case Rep. 2022 Aug;11(3):339-346. doi:10.1007/s13730-021-00682-y. Epub 2022 Jan 13; Jarrot PA, Chiche L, Hervier B, et al. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis. Medicine (Baltimore). 2016 May;95(22):e3748. doi:10.1097/MD.0000000000003748.; Derrett-Smith EC, Nihtyanova SI, Harvey J,et al. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology (Oxford). 2013 Oct;52(10):1824-31. doi:10.1093/rheumatology/ket213. Epub 2013 Jul 5.; Clark КЕ. Review of systemic sclerosisand antineutrophil cytoplasmic antibody vasculitis overlap: Using autoantibodies for a personalised medicine approach. J Scleroderma Relat Disord. 2023 Feb;8(1):7-13. doi:10.1177/23971983221126850.; Ruffatti A, Sinico RA, Radice A, et al.Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol. 2002 May;29(5):918-23.; Moxey J, Huq M, Proudman S, et al. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Res Ther. 2019 Feb 14;21(1):57. doi:10.1186/s13075019-1839-5.; Arad U, Balbir-Gurman A, Doenyas-Barak K, et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum. 2011 Oct;41(2):223-9. doi:10.1016/j.semarthrit.2010.11.001. Epub 2011 Feb 1.; Quemeneur T, Mouthon L, Cacoub P, et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine. 2013 Jan;92(1): 1-9. doi:10.1097/MD.0b013e31827781fd.; Böttinger EP, Niles JL, Collins AB, et al. Antineutrophil cytoplasmic autoantibody-associated vasculitis presenting as Sjögren's syndrome. Arthritis Rheum. 1992 Nov;35(11): 1373-6. doi:10.1002/art.1780351120.; Coustal С, Guillope В, Serrand С, et al.Sjögren syndrome overlapping with ANCAassociated vasculitis: Four additional cases and systematic literature review. Autoimmun Rev. 2022 Jun;21(6):103099. doi:10.1016/j.autrev.2022.103099. Epub 2022 Apr 19.; Pillay SS, Nune A, Manzo C, et al. A caseof anti-neutrophil cytoplasmic antibody-associated vasculitis masquerading as Sjögren syndrome. Int J Rheum Dis. 2023 Dec;26(12): 2555-2558. doi:10.1111/1756-185X.14823.; Kaynar K, Güvercin B, Sengör A, Mungan S. A case of Sjögren syndrome and antineutrophil cytoplasmic antibody-associated vasculitis. Reumatismo. 2023 Jul 17;75(2). doi:10.4081/reumatismo.2023.1564; Font J, Ramos-Casals M, Cervera R, et al. Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Br J Rheumatol. 1998 Dec; 37(12):1287-91. doi:10.1093/rheumatology/37.12.1287.; Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019 Sep;1(1):e55-e65. doi:10.1016/S26659913(19)30017-7. Epub 2019 Aug 28.; Mbengue M, Goumri N, Niang A. IgG4related kidney disease: pathogenesis, diagnosis, and treatment. Clin Nephrol. 2021 Jun; 95(6):292-302. doi:10.5414/CN110492.; Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020 Jan;72(1):7-19. doi:10.1002/art.41120. Epub 2019 Dec 2.; Danlos F, Rossi GM, Blockmans D, et al. Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome. Autoimmun Rev. 2017 Oct;16(10):1036-1043. doi:10.1016/j.autrev.2017.07.020. Epub 2017 Aug 2.; Sekiguchi H, Horie R, Kanai M, et al. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatology. 2016 Sep;68(9):2290-9. doi:10.1002/art.39686.; Martin-Nares E, Hernandez-Molina G. What is the mean-ing of ANCA positivity in IgG4-related disease? Rheumatology (Oxford). 2021 Aug 2;60(8):3845-3850. doi:10.1093/rheumatology/keab124.; Bello F. The uncertain meaning of ANCApositivity in IgG4-related disease. Rheumatology (Oxford). 2021 Aug 2;60(8):3492-3493. doi:10.1093/rheumatology/keab368.; Kuske L, Khalifa А, Wibisono А, et al. MPO-ANCA-positive granulomatosis with polyangiitis and concurrent IgG4-related disease with periaortitis and tubulointerstitial nephritis: A case report of a new overlap syndrome? Int J Rheum Dis. 2023 Sep;26(9):18211825. doi:10.1111/1756-185X.14680; Wu HHL, Wang CCY, Woywodt A, Ponnusamy A. Concurrent presentation of IgG4related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis. Clin Nephrol Case Stud. 2022 Jul 4;10:47-53. doi:10.5414/CNCS110852.eCollection 2022.; Gilani SI, Alexander MP, Nasr SH, et al. Clinicopathologic findings in mass forming ANCA-associated vasculitis. Kidney Int Rep. 2022 Sep 29;7(12):2709-2713. doi:10.1016/j.ekir.2022.09.019.eCollection 2022 Dec.; Ferry JA, Klepeis V, Sohani AR, et al. IgG4-related orbital disease and its mimics in a Western population. Am J Surg Pathol. 2015 Dec;39(12):1688-700. doi:10.1097/PAS.0000000000000497.; Kurita N, Mise N, Fujii A, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with rheumatoid arthritis: a comparison of patients without rheumatoid arthritis. Clin Exp Nephrol. 2010 Aug;14(4):325-32. doi:10.1007/s10157-010-0278-z. Epub 2010 Mar 26.; Draibe J, Salama AD. Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome. Springerplus. 2015 Feb 1;4:50. doi:10.1186/s40064-015-0835-8.eCollection 2015.; Mustila A, Korpela M, Mstonen J, et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum. 1997 Apr;40(4):710-7. doi:10.1002/art.1780400417.; Calabresi P, Edwards EA, Schilling RF. Fluorescent antiglobulin studies in leukopenic and related disorders. J Clin Invest. 1959 Nov;38(11):2091-100. doi:10.1172/JCI103987.; Kallenberg CG, Mulder AH, Tervaert JW.Antineutrophil cytoplasmic antibodies: a stillgrowing class of autoantibodies in inflammatory disorders. Am J Med. 1992 Dec;93(6): 675-82. doi:10.1016/0002-9343(92)90202-m.; Vasiliauskiene L, Wiik A, Høier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis. 2001 May;60(5):459-66. doi:10.1136/ard.60.5.459.; Vittecoq O, Jouen-Beades F, Krzanowska Ket al. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology (Oxford). 2000 May; 39(5):481-9. doi:10.1093/rheumatology/39.5.481.; Kida I, Kobayashi S, Takeuchi K, et al.Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011 Feb;21(1):43-50. doi:10.1007/s10165010-0356-9. Epub 2010 Sep 28.; Gуis M, Messias A, Carvalho D et al. MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature. J Nephropathol. 2017 Mar;6(2):58-62. doi:10.15171/jnp.2017.10. Epub 2016 Oct 27.; Wu Н, Lu Y, Hu R, et al. Anti-neutrophilcytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis. BMC Nephrol. 2022 Apr 22;23(1):155. doi:10.1186/s12882-022-02788-6.; Nada AK, Torres VE, Ryu JH, et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990 Jun; 65(6):847-56. doi:10.1016/s0025-6196(12) 62575-0.; Arimura Y, Minoshima S, Tanaka U, et al.Pulmonary involvement in patients with myeloperoxidase specific-antineutrophil cytoplasmic antibody. Ryumachi Rheum. 1995 Feb; 35(1):46-55.; Pella E, Iatridi F, Sgouropoulou V, et al.Pulmonary involvement in antineutrophil cytoplasmic antibody-associated vasculitides. Int J Rheum Dis. 2024 Jan;27(1):e14933. doi:10.1111/1756-185X.14933.; Yamaguchi K, Yamaguchi A, Ito M, et al. Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. Clin Rheumatol. 2023 Feb;42(2):479-488. doi:10.1007/s10067-022-06388-5.; Steward M, Thould H, Myat Noe Khin A, Gibbons MA. Interstitial Lung Disease and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Review. Immunol Allergy Clin North Am. 2023 May;43(2):379-388. doi:10.1016/j.iac.2023.01.001.; Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):221-231.; Matsuda S, Kotani T, Suzuka T, et al. Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Sci Rep. 2021 Jan 15;11(1):1490. doi:10.1038/s41598-021-81311-7.; Шелыгин ЮА, Ивашкин ВТ, Ачкасов СИи др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10-49.; Drury B, Hardisty G, Gray RD, Ho GT.Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cell Mol Gastroenterol Hepatol. 2021;12(1):321-333. doi:10.1016/j.jcmgh.2021.03.002. Epub 2021 Mar 6.; Calabresi P, Thayer WR Jr, Spiro HM. Demonstration of circulating antinuclear globulins in ulcerative colitis. J Clin Invest. 1961 Dec; 40(12):2126-33. doi:10.1172/JCI104438.; Prideaux L, De Cruz P, Ng SC, Kamm MA.Serological antibodies in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis. 2012 Jul;18(7):1340-55. doi:10.1002/ibd.21903.; Andalucнa C, Martinez-Prat L, Bentow C,et al. Clinical Validity of Anti-Proteinase 3 Antibodies in Patients with Inflammatory Bowel Disease: A Short Meta-Analysis. Diagnostics (Basel). 2023 Dec 16;13(24):3682. doi:10.3390/diagnostics13243682.; Александрова ЕН, Новиков АА, Лукина ГВ, Парфенов АИ. Клиническое значение антител при воспалительных заболеваниях кишечника. Терапевтический архив. 2021;93(2):228-235.; Pagnoux C, Mahr A, Cohen P, Guillevin L.Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg–Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005 Mar;84(2):115-128. doi:10.1097/01.md.0000158825.87055.0b.; Beretta-Piccoli ВТ, Mieli-Vergani G, Vergani D. Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice. Clin Rev Allergy Immunol. 2022 Oct;63(2):124-137. doi:10.1007/s12016-021-08888-9; De Riva V, Celadin M, Pittoni M, et al. What is behind the presence of antineutrophil cytoplasmatic antibodies in chronic liver disease? Liver Int. 2009 Jul;29(6):865-70. doi:10.1111/j.1478-3231.2009.01989.x.; Hutson TE, Hoffman GS. Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res. 2000 Dec;13(6): 417-23. doi:10.1002/1529-0131(200012)13:63.0.co;2-t.; Chiao-Chi Ou , Yen-Ching Wu , JunPeng, et al. Chen Association of atypical antineutrophil cytoplasmic antibody with comorbidities and outcome in a hospital-based population. Heliyon. 2024 Jan 6;10(1):e24105. doi:10.1016/j.heliyon.2024.e24105.; Houben E, Bax WA, van Dam B, et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine (Baltimore). 2016 Oct; 95(40):e5096. doi:10.1097/MD.0000000000005096.; Zhang CY, Miao R, Li W, et al. Lung adenocarcinoma and sequential antineutrophil cytoplasmic antibody-associated vasculitis: a case report. J Int Med Res. 2021 Feb;49(2): 300060521993319. doi:10.1177/0300060521993319.; Quack H, Erpenbeck L, Wolff HA, et al.Oxaliplatin-induced leukocytoclastic vasculitis under adjuvant chemotherapy for colorectal cancer: two cases of a rare adverse event. Case Rep Oncol. 2013 Dec 11;6(3):609-15. doi:10.1159/000357166.; Mattiassich G, Egger M, Semlitsch G,Rainer F. Occurrence of relapsing polychondritis with a rising cANCA titre in a cANCApositive systemic and cerebral vasculitis patient. BMJ Case Rep. 2013 Feb 15;2013: bcr2013008717. doi:10.1136/bcr-2013008717.; Iwuji K, Kanu A, Stroever S, et al. Clinicalsignificance of BPI-ANCA in patients with cystic fibrosis: a single center prospective study. Sci Rep. 2023 Oct 24;13(1):18138. doi:10.1038/s41598-023-45273-2.; Alqurashi AS, Aly MH, Mohammed A, et al. Dermatological Lesions of Cholesterol Syndrome and Kaposi Sarcoma Mimic Primary Systemic Vasculitis: Case report study. Sultan Qaboos Univ Med J. 2023 May;23(2): 256-258. doi:10.18295/squmj.2.2022.018.; Konstantinov KN, Ulff-Møller CJ, Tzamaloukas AH. Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev. 2015 Mar;14(3):201-3. doi:10.1016/j.autrev.2014.10.020.; Banjongjit А, Thammathiwat Т, Townamchai N, Kanjanabuch Т. SARS-CoV-2 infection associated with antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN): a systematic review and two case reports. J Nephrol. 2024 Jan; 37(1):53-63. doi:10.1007/s40620-023-01777-8. Epub 2023 Nov 6.; Schaap CM, Krol RM, Remmelts HHF, et al. The effect of nasal Staphylococcus aureus colonization and antibiotic treatment on disease activity in ANCA-associated vasculitis: a retrospective cohort study in the Netherlands. Rheumatol Int. 2023 Mar;43(3):467-475. doi:10.1007/s00296-022-05228-8.; Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Oct;41(10):2949-2960. doi:10.1007/s10067022-06240-w.; Huan G, Yang G, Xiao-Yu Q, et al. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):475-478. doi:10.1590/0037-8682-0400-2017.; Culerrier J, Nguyen Y, Karadag O, Bilge SY. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicenter retrospective case-control study. Rheumatology (Oxford). 2023 Jun 24:kead319. doi:10.1093/rheumatology/kead319; Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020 Jan;75(1):124-137. doi:10.1053/j.ajkd.2019.04.031.; Yaseen K, Nevares A, Tamaki H. A Spotlight on Drug-Induced Vasculitis. Curr Rheumatol Rep. 2022 Nov;24(11):323-336. doi:10.1007/s11926-022-01088-0; Seida I, Seida R, Elsalti A, Mahroum N.Vaccines and Autoimmunity-From Side Effects to ASIA Syndrome. Medicina (Kaunas). 2023 Feb 14;59(2):364. doi:10.3390/medicina59020364; Nune A, Durkowski V, Pillay SS, et al. New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARSCoV-2 Vaccinations until May 2023: A Systematic Review. Vaccines (Basel). 2023 Oct 8; 11(10):1571. doi:10.3390/vaccines11101571; Watad A, Quaresma M, Bragazzi NL, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld’s syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol. 2018 Feb;37(2):483-493. doi:10.1007/s10067-017-3748-9.; https://mrj.ima-press.net/mrj/article/view/1556

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1556
https://doi.org/10.14412/1996-7012-2024-2-7-15

المؤلفون: O. N. Egorova, G. M. Tarasova, G. M. Koylubaeva, A. Yu. Sukhanina, I. A. Guseva, A. M. Bolotbekova, G. Suyunbai kyzy, A. T. Turatbekova, A. A. Okunova, A. O. Abdykerimov, T. M. Reshetnyak, О. Н. Егорова, Г. М. Тарасова, Г. М. Койлубаева, А. Ю. Суханина, И. А. Гусева, А. М. Болотбекова, Г. Суйунбай кызы, А. Т. Туратбекова, А. А. Окунова, А. О. Абдыкеримов, Т. М. Решетняк

المساهمون: Статья подготовлена в рамках научно-исследовательской работы (№/№ государственных заданий РК 122040400024-7) и международного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) и Национального центра кардиологии и терапии им. акад. Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской республики (Кыргызстан).

المصدر: Modern Rheumatology Journal; Том 18, № 1 (2024); 101-108 ; Современная ревматология; Том 18, № 1 (2024); 101-108 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: терапия, diagnostics, disease activity, therapy, диагностика, активность заболевания

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1539/1445; Seko Y , Takahashi N, Tada Y, et al. Restricted usage of T-cell receptor VgammaVdelta genes and expression of costimulatory molecules in Takayasu's arteritis. Int J Cardiol. 2000 Aug 31;75 Suppl 1:S77-83; discussion S85-7. doi:10.1016/s0167-5273(00)00194-7.; Ohigashi H, Haraguchi G, Konishi M, et al. Improved prognosis of Takayasu arteritis over the past decade. Circ J. 2012;76(4): 1004-11. doi:10.1253/circj.cj-11-1108. Epub 2012 Feb 2.; Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US Cohort of 126 patients. Mayo Clin Proc. 2013 Aug;88(8): 822-30. doi:10.1016/j.mayocp.2013.04.025. Epub 2013 Jul 10.; Gudbrandsson B, Molberg O, Garen T, Palm O. Prevalence, Incidence, and Disease Characteristics of Takayasu Arteritis by Ethnic Background: Data From a Large, PopulationBased Cohort Resident in Southern Norway. Arthritis Care Res (Hoboken). 2017 Feb;69(2): 278-285. doi:10.1002/acr.22931. Epub 2016 Dec 31.; Watanabe Y, Miyata T, Tanemoto K. Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan: Age and Sex Specificity. Circulation. 2015 Nov 3;132(18):1701-9. doi:10.1161/CIRCULATIONAHA.114. 012547. Epub 2015 Sep 9.; Firouzi A , Khalilipur E, Khajali Z, et al. The Treatment Dilemma of Arteriopathy in Takayasu Arteritis – A State-of-the-Art Approach. Curr Probl Cardiol. 2023 Jan; 48(1): 101359. doi:10.1016/j.cpcardiol.2022.101359.; Zhang Z, Wang W, Zhou M, et al. Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences. Ann Vasc Surg. 2020 Jul:66:309-317. doi:10.1016/j.avsg.2019.12.007. Epub 2019 Dec 18.; Rutter M, Bowley J, Lanyon PC, et al. A Systematic Review and Meta-Analysis of the Incidence Rate of Takayasu Arteritis. Rheumatology (Oxford). 2021; Nov 3;60(11): 4982-4990. doi:10.1093/rheumatology/ keab406.; Isohisa I, Numano F, Maezawa H, Sasazuki T. HLA-Bw52 in Takayasu disease. Tissue Antigens. 1978 Oct;12(4):246-8. doi:10.1111/j.1399-0039.1978.tb01332.x.; Naito S, Arakawa K, Saito S, et al. Takayasu's disease: association with HLA-B5. Tissue Antigens. 1978 Aug;12(2):143-5. doi:10.1111/j.1399-0039.1978.tb01310.x.; Terao C. Revisited HLA and non-HLA genetics of Takayasu arteritis – where are we? J Hum Genet. 2016 Jan;61(1):27-32. doi:10.1038/jhg.2015.87. Epub 2015 Jul 16.; Saruhan-Direskeneli G, Hughes T, Aksu K, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet. 2013 Aug 8;93(2):298-305. doi:10.1016/j.ajhg.2013.05.026. Epub 2013 Jul 3.; Renauer PA, Saruhan-Direskeneli G, Coit P, et al. Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. Arthritis Rheumatol. 2015 May;67(5): 1361-8. doi:10.1002/art.39035.; Renauer P, Sawalha AH. The genetics of Takayasu arteritis. Presse Med. 2017 Jul-Aug; 46(7-8 Pt 2):e179-e187. doi:10.1016/j.lpm.2016.11.031. Epub 2017 Jul 26.; Ortiz-Fernandez L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet. 2021 Jan 7;108(1): 84-99. doi:10.1016/j.ajhg.2020.11.014. Epub 2020 Dec 11.; Carmona FD, Coit P, Saruhan-Direskeneli G, et al. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep. 2017 Mar 9:7:43953. doi:10.1038/srep43953.; Jin K, Wen Z, Wu B, et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J Clin Invest. 2021 Jan 4;131(1):e136042. doi:10.1172/JCI136042.; Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018 Sep;37(9):2579-2584. doi:10.1007/s10067-018-4177-0. Epub 2018 Jun 19.; Pryshchep O, Ma-Krupa W, Younge BR, et al.Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation. 2008 Sep 16;118(12):1276-84. doi:10.1161/CIRCULATIONAHA.108.789172. Epub 2008 Sep 2.; Kaiser M, Younge B, Björnsson J, et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol. 1999 Sep; 155(3):765-74. doi:10.1016/S0002-9440(10) 65175-9.; Desbois AC, Regnier P, Quiniou V, et al. Specific Follicular Helper T Cell Signature in Takayasu Arteritis. Arthritis Rheumatol. 2021 Jul;73(7):1233-1243. doi:10.1002/art.41672. Epub 2021 May 19.; Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012 Jan;71(1):75-9. doi:10.1136/ard.2011.153007. Epub 2011 Sep 27.; Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/ EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022 Dec;81(12): 1654-1660. doi:10.1136/ard-2022-223482. Epub 2022 Nov 9.; Misra DP, Singh K, Rathore U, et al. Management of Takayasu arteritis. Best Pract Res Clin Rheumatol. 2023 May 26;101826. doi:10.1016/j.berh.2023.101826.; As C, Danda D. Current Diagnosis and Management of Takayasu Arteritis. Int Heart J. 2023;64(4):519-534. doi:10.1536/ihj.23-195.; Quinn KA, Gribbons KB, Carette S, et al. Patterns of clinical presentation in Takayasu’s arteritis. Semin Arthritis Rheum. 2020 Aug; 50(4):576-581. doi:10.1016/j.semarthrit.2020. 04.012. Epub 2020 May 19.; Keenan NG, Mason JC, Maceira A, et al. Integrated cardiac and vascular assessment in takayasu arteritis by cardiovascular magnetic resonance. Arthritis Rheum. 2009 Nov;60(11): 3501-9. doi:10.1002/art.24911.; Койлубаева ГМ, Болотбекова АМ, Бейшенкулов МТ и др. Клинические проявления поражения сердечно-сосудистой системы и предикторы неблагоприятного прогноза артериита Такаясу у кыргызских пациентов. Научно-практическая ревматология. 2023;61(5):576-583.; Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020 Jan;79(1):19-30. doi:10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.; Maz M, Chung SA, Abril A, et al. American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu Arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65. doi:10.1002/art.41774 31. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing takayasu arteritis with methotrexate. Arthritis Rheum. 1994 Apr;37(4):578-82. doi:10.1002/art.1780370420.; Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol. 2003 Aug;30(8):1793-8.; Dai D, Wang YY, Jin H, et al. The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Int. 2017 Jul;37(7):1083-1088. doi:10.1007/s00296-017-3704-7. Epub 2017 Mar 31.; de Souza AWS, de Almeida Agustinelli R, de Cinque Almeida H, et al. Leflunomide in Takayasu arteritis – a long term observational study. Rev Bras Reumatol Engl Ed. 2016 JulAug;56(4):371-5. doi:10.1016/j.rbre.2016.02.003. Epub 2016 Mar 2.; Sun Y, Ma L, Ma L, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. Rheumatol Int. 2017 Dec;37(12):2019-2026. doi:10.1007/s00296-017-3847-6. Epub 2017 Oct 13.; Misra DP, Rathore U, Patro P, et al. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis. Clin Rheumatol. 2021 Nov;40(11):4391-4416. doi:10.1007/s10067-021-05743-2. Epub 2021 May 1.; Barra L, Yang G, Pagnoux C. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. Autoimmun Rev. 2018 Jul;17(7):683-693. doi:10.1016/j.autrev.2018.01.019. Epub 2018 May 2.; Mertz P, Kleinmann JF, Lambert M, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev. 2020 Oct;19(10):102634. doi:10.1016/j.autrev.2020.102634. Epub 2020 Aug 13.; Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol. 2014 Jan;26(1):7-15. doi:10.1097/BOR.0000000000000004.; Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation. 2015 Nov 3;132(18):1693-700. doi:10.1161/CIRCULATIONAHA.114.014321. Epub 2015 Sep 9.; Suematsu R, Tashiro S, Ono N, et al. Successful golimumab therapy in four patients with refractory Takayasu's arteritis. Mod Rheumatol. 2018 Jul;28(4):712-715. doi:10.3109/14397595.2015.1134393. Epub 2016 Mar 21.; Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of takayasu arteritis. Rheumatology (Oxford). 2018 Dec 1;57(12):2101-2105. doi:10.1093/rheumatology/key197.; Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008 Apr;58(4):1197-200. doi:10.1002/art.23373.; Abisror N, Mekinian A, Lavigne C, et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev. 2013 Oct;12(12):1143-9. doi:10.1016/j.autrev.2013.06.019. Epub 2013 Jun 29.; Canas CA, Canas F, Izquierdo JH, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in colombian patients with takayasu arteritis. J Clin Rheumatol. 2014 Apr;20(3):125-9. doi:10.1097/RHU.0000000000000098.; Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumatol. 2016 May;28(3):211-7. doi:10.1097/BOR.0000000000000265.; Wang J, Kong X, Ma L, et al. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study. Rheumatology (Oxford). 2023 Aug 4:kead387. doi:10.1093/rheumatology/kead387. Online ahead of print.; Upendra Rathore U, Thakare DR, Patro P, et al. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol. 2022 Jan;41(1):33-44. doi:10.1007/s10067-021-05973-4. Epub 2021 Nov 3; Kong X, Sun Y, Dai X, et al. Treatment efficacy and safety of tofacitinib vs. methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2022 Jan;81(1): 117-123. doi:10.1136/annrheumdis-2021-220832.; Li J, Li M, Tian X, Zeng X. Tofacitinib in patients with refractory Takayasu's arteritis. Rheumatology (Oxford). 2020 Nov 1;59(11): e95-e98. doi:10.1093/rheumatology/keaa281.; Sato S, Matsumoto H, Temmoku J, et al. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi:10.1093/rheumatology/kez580.; Palermo A, Marvisi C, Casali M, et al. Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases. Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):234-235. Epub 2020 Jan 9.; Regnier P, Le Joncour A, MaciejewskiDuval A, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020 Jul;79(7):951-959. doi:10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25.; Watanabe R. JAK inhibitors as promising agents for refractory Takayasu arteritis. Ann Rheum Dis. 2022 Apr;81(4):e67. doi:10.1136/ annrheumdis-2020-217577; Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg. 2000 Mar;8(2):141-8. doi:10.1016/s0967-2109(99)00100-3.; Galarza C, Valencia D, Tobуn GJ, et al. Should rituximab be considered as the firstchoice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008 Feb;34(1):124-8. doi:10.1007/s12016-007-8028-z.; Pazzola G, Muratore F, Pipitone N, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018 Jul 1; 57(7):1151-55. doi:10.1093/rheumatology/kex249.; Mekinian A, Noe L, Salvarani C, et al. Effectiveness and safety of rituximab in Takayasu arteritis: data from a multicenter retrospective study. Joint Bone Spine. 2023 Oct 31; 91(2):105658. doi:10.1016/j.jbspin.2023.105658.; Nakagomi D, Kronbichler A, Witte T, et al. Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018 Jul 1;57(7):1309-1310. doi:10.1093/rheumatology/kex493.; Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol. 2014 Aug;33(8):1183-4. doi:10.1007/s10067-014-2506-5. Epub 2014 Jan 31.; Mutoh T, Ishii T, Shirai T, et al. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. Rheumatol Int. 2019 Nov;39(11):1989-1994. doi:10.1007/s00296-019-04390-w. Epub 2019 Aug 6.; Blache U, Tretbar S, Koehl U, et al. CAR T cells for treating autoimmune diseases. RMD Open. 2023 Nov 23;9(4):e002907. doi:10.1136/rmdopen-2022-002907.; Kwon OC, Oh JS, Park MC, et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol. 2019 Jul 15:287:111-115. doi:10.1016/j.ijcard.2019.02.046. Epub 2019 Feb 20.; Laurent C, Prieto-Gonzalez S, Belnou P, et al. Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Sci Rep. 2021 Jul 13;11(1):14404. doi:10.1038/s41598-021-93416-0.; Shi G, Hua M, Xu Q, Ren T. Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebocontrolled trial. Immunobiology. 2017 Feb; 222(2):164-168. doi:10.1016/j.imbio.2016.10.008. Epub 2016 Oct 14.; Shao N, Jia H, Li Y, Li J. Curcumin im proves treatment out come of Takayasu arteritis patients by reducing TNF-α: a randomized placebo-controlled double-blind clinical trial. Immunol Res. 2017 Aug;65(4):969-974. doi:10.1007/s12026-017-8917-z.; Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. doi:10.1136/annrheumdis-2017-212649. Epub 2018 Jan 22.; Padiyar S, Manikuppam P, Kabeerdoss J, et al. Update on pregnancy in Takayasu arteritis-A narrative review. Int J Rheum Dis. 2021 Jun;24(6):758-765. doi:10.1111/1756-185X.14109. Epub 2021 Apr 18.; Chen ST, Luo CB, Guo WY, Chang FC. Endovascular management of symptomatic stenosis of supra-aortic arteries in patients with Takayasu arteritis. J Chin Med Assoc. 2021 Mar 1;84(3):303-308. doi:10.1097/JCMA.0000000000000479.; Han HS, Yoon KW, Heo SH, et al. Aortocarotid bypass in patients with Takayasu’s arteritis. Ann Surg Treat Res. 2017 Sep;93(3): 143-151. doi:10.4174/astr.2017.93.3.143. Epub 2017 Aug 30.; Xiao Y, Zhou J, Wei X, et al. Outcomes of different treatments on Takayasu’s arteritis. J Thorac Dis. 2016 Sep;8(9):2495-2503. doi:10.21037/jtd.2016.08.12.; Chen ZG, Chen YX, Diao YP, et al. Simultaneous Multi-Supra-Aortic Artery Bypass Successfully Implemented in 17 Patients with Type I Takayasu Arteritis. Eur J Vasc Endovasc Surg. 2018 Dec;56(6):903-909. doi:10.1016/j.ejvs.2018.08.044. Epub 2018 Oct 11.; Fu Y, Chen Y. Operative experience on descending aorta with Takayasu Arteritis: a review. Front Cardiovasc Med. 2023 Jun 21:10:1181285. doi:10.3389/fcvm.2023. 1181285. eCollection 2023.; https://mrj.ima-press.net/mrj/article/view/1539

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1539
https://doi.org/10.14412/1996-7012-2024-1-101-108

المؤلفون: O. N. Egorova, G. M. Tarasova, A. V. Datsina, E. G. Sazhina, О. Н. Егорова, Г. М. Тарасова, А. В. Дацина, Е. Г. Сажина

المساهمون: The article was prepared within the framework of a research work, №/№ of state assignments РК 122040400024-7. The investigation has not been sponsored, Статья подготовлена в рамках научно-исследовательской работы, № государственного задания РК 122040400024-7. Исследование не имело спонсорской поддержки

المصدر: Modern Rheumatology Journal; Том 18, № 3 (2024); 78-84 ; Современная ревматология; Том 18, № 3 (2024); 78-84 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: высокие и низкие дозы, rheumatic diseases, indications for use, high and low doses, ревматические заболевания, показания к назначению

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1592/1475; Bayry J, Misra N, Latry V et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165-9. doi:10.1016/s1246-7820(03)00035-1.; Greenberg M, Frant S, Rutstein D. «Gammaglobulin» and «placental globulin»; comparison of their effectiveness in prevention and modification of measles. JAMA. 1944;126(15): 944-47.; Ordman CW, Jennings JR, Janeway CA. Chemical, Clinical and Immunological studies on the products of human plasma fractionation. XII. The Use of Concentrated Normal Human Serum Gamma Globulin (Human Immune Serum Globulin) in the Prevention and Attenuation of Measles. J Clin Invest. 1944 Jul;23(4):541-9. doi:10.1172/JCI101519.; Stokes J, Neefe J. The prevention and attenuation of infectious hepatitis by gamma globulin. Preliminary note. JAMA.1945;127(3): 144-45.; Вruton O. Agammaglobulinemia. Pediatrics.1952;(9):722-28.; Imbach P, Barandun S, Baumgartner C, et al.High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981 Feb;36(1):81-6.; Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol. 2014;164(2):151-66. doi:10.1159/000363445. Epub 2014 Jul 10.; Wood JG, Heywood AE, Dennington PM, et al. Trends in intravenous immunoglobulin use in New South Wales, Australia. Intern Med J. 2024 Jan;54(1):149-156. doi:10.1111/imj.16175.; Velikova T, Sekulovski M, Bogdanova S, et al. Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine. Antibodies (Basel). 2023 Mar 2;12(1):20. doi:10.3390/antib12010020.; National Blood Authority. National report on the issue and use of immunoglobulin (IVIg). Annual report 2015–16. Canberra: Common-wealth of Australia; 2017. https://www.blood.gov.au/data-analysis-reporting.; Tavee J, Brannagan TH 3 rd , Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023 Oct; 68(4):356-74. doi:10.1002/mus.27922.; Danieli MG, Antonelli E, Auria SS, et al. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev. 2023 Nov; 22(11):103451. doi:10.1016/j.autrev.2023.103451.; Hadaschik E, Eming R, French LE, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. Hautarzt. 2020 Jul;71(7):542-52. doi:10.1007/s00105-020-04610-6.; Середавкина НВ, Решетняк ТМ, Насонов ЕЛ. Место внутривенного иммуноглобулина при ревматических заболеваниях. Современная ревматология. 2015;9(4):59-67. doi:10.14412/1996-7012-2015-4-59-67.; Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. doi:10.1056/NEJMra1009433.; Лазанович ВА, Просекова ЕВ. Внутривенные иммуноглобулины: механизмы терапевтических эффектов. Медицинская иммунология. 2014;16(4):311-22.; Shoenfeld Y, Gershwin ME. Intravenous immunoglobulin. Clinic Rev Allerg Immunol. 2005;29:165-66. doi:10.1385/CRIAI:29:3:165.; Bayry J,Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1): 9-15. doi:10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.; Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011 Oct;10(12):809-10. doi:10.1016/j.autrev.2011.02.007. Epub 2011 Mar 2.; Blank M, Bashi T, Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol. 2014:1060:353-61. doi:10.1007/978-1-62703-586-6_18.; Hulett MD, Hogarth PM. Molecular Basis of Fc Receptor Function. Adv Immunol. 1994; 57:1-127. doi:10.1016/s0065-2776(08)60671-9.; Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):421-6. doi:10.1016/s0091-6749(99)70466-5.; Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012 Apr;42(2):247-55. doi:10.1007/s12016-011-8278-7.; Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi:10.1007/s13311-021-01108-4. Epub 2021 Nov 11.; Benavides-Villanueva F, Loricera J, Calvo-Rio V, et al, Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med. 2023 Nov;117:78-84. doi:10.1016/j.ejim.2023.06.021.; Yates M, Watts AR, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.; Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007 Mar;6(4):257-9. doi:10.1016/j.autrev.2006.08.011. Epub 2006 Aug 28.; Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi:10.1186/s13075-023-03232-2.; Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 Dec;29(3):219-28. doi:10.1385/CRIAI:29:3:219.; Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395-402. doi:10.1016/j.humimm.2005.01.022.; Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008 Jan;10(1):55-7.; Binello N, Cancelli C, Passalacqua S, et al. Use of intravenous immunoglobulin therapy at unconventional doses in refractory fulminant systemic lupus erythematosus. Eur J Case Rep Intern Med. 2018 Sep 27;5(9):000934. doi:10.12890/2018_000934. eCollection 2018.; Schroeder J, Zeuner AR, Euler HH, Lцffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol. 1996 Jan;23(1):71-5.; Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus. 1999;8(9):705-12. doi:10.1191/096120399678841007.; Tenti S, Cheleschi S, Guidelli GM, et al. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev. 2016 Mar;15(3):226-35. doi:10.1016/j.autrev.2015.11.009. Epub 2015 Dec 1.; Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in anti-phospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012 May-Jun;30(3):409-13. Epub 2012 Jun 26.; Ruiz-Irastorza G, Espinosa G, Frutos M, et al. Diagnosis and treatment of lupus nephritis: Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012:32 Suppl 1:1-35. doi:10.3265/Nefrologia.pre2011.Dec.11298.; Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid anti-bodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994 Aug;7(4):537-48. doi:10.1006/jaut.1994.1039.; Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13(6):478-80. doi:10.1191/0961203303lu1035cr.; Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015 Mar;54(3):383-91. doi:10.1093/rheumatology/keu429. Epub 2014 Nov 17.; Bitsadze V, Yakubova F, Khizroeva J, et al. Catastrophic Antiphospholipid Syndrome. Int J Mol Sci. 2024 Jan 4; 25(1):668. doi:10.3390/ijms25010668.; Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1748-55. doi:10.1002/acr.20325.; Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009 May-Jun;187(3):201-6. doi:10.1007/s00408-009-9146-6. Epub 2009 Apr 22.; Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb;46(2):467-74. doi:10.1002/art.10053.; Speca S, Farhat MM, Jendoubi M, et al. Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis. Sci Rep. 2023 Sep 12;13(1):15102. doi:10.1038/s41598-023-42464-9.; Tandaipan J, Guillen-Del-Castillo A, Simeуn-Aznar CP, et al. Immunoglobulins in systemic sclerosis management. A large multi-center experience. Autoimmun Rev. 2023 Nov; 22(11):103441. doi:10.1016/j.autrev.2023.103441.; Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 2023 Sep 1; 62(9):3139-45. doi:10.1093/rheumatology/kead093.; Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in high skin mice. Arthritis Rheum. 2002 Jun;46(6):1689-90. doi:10.1002/art.10363.; Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995 Jul;101(1):2-7. doi:10.1111/j.1365-2249.1995.tb02268.x.; Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis. Clin Rev Allergy Immunol. 2005 Dec;29(3): 237-45. doi:10.1385/CRIAI:29:3:237.; Kivity S, Katz U, Daniel N, et al. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. doi:10.1007/s12016-009-8155-9.; Chung SA, Langford CA, Maz M, et al. 2021 american college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi:10.1002/acr.24634. Epub 2021 Jul 8.; Hellmich В, Sanchez-Alamo В, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi:10.1136/ard-2022-223764.; Jayne D, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000 Jul;93(7):433-9. doi:10.1093/qjmed/93.7.433.; Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (Oxford). 2020 May 1; 59(5):959-967. doi:10.1093/rheumatology/kez311.; Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6): 488-98. doi:10.7326/0003-4819-116-6-488.; Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi:10.1002/art.23147.; Fortin PM, Tejani AM, Bassett K, Musini V. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2013 Jan 31;2013(1): CD007057. doi:10.1002/14651858.CD007057.pub3.; Weishaupt C, Strölin A, Kahle B, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi:10.1111/jdv.15639. Epub 2019 May 14.; Ozden MG, Ozdemir H, Senturk N. Intravenous immunoglobulin in resistant livedoid vasculopathy: analysis of a case series. Dermatol Ther. 2020 Mar;33(2):e13229. doi:10.1111/dth.13229. Epub 2020 Feb 4.; Kofler K, Strölin A, Geiger V, Kofler L. Intravenous immunoglobulin therapy in livedoid vasculopathy: retrospective observation of clinical outcome and patient's activity level. J Cutan Med Surg. 2021 Sep;25(5):504-10. doi:10.1177/12034754211003525.; Cantarini L, Stromillo ML, Vitale A, et al. Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Isr Med Assoc J. 2016 Mar-Apr;18 (3-4):238-42.; Seeliger T, Prenzler NK, Gingele S, et al. Neuro-Sjцgren: Peripheral Neuropathy With Limb Weakness in Sjцgren’s Syndrome. Front Immunol. 2019 Jul 11:10:1600. doi:10.3389/fimmu.2019.01600. eCollection 2019.; Mehmood M, Jog A, Niazi M, et al. Atypical 's syndrome initially presenting as lymphocytic interstitial pneumonitis followed by immune thrombocytopenia. Case Rep Rheumatol. 2021 Mar 15;2021:6681590. doi:10.1155/2021/6681590.; Noh G, Han CW. Intravenous Immune Globulin (IVIG) Therapy After Unsuccessful Treatment with Corticosteroid and Cyclosporine A in Pfeifer-Weber-Christian Disease: A Case Report. Am J Case Rep. 2021 Jan 4; 22:e929519. doi:10.12659/AJCR.929519; Shen X, Wang F. The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score-matched pilot study. Int J Rheum Dis. 2023 Sep; 26(9):1745-1750. doi:10.1111/1756-185X.14808.; Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015 Aug; 14(8):651-8. doi:10.1016/j.autrev.2015.04.003. Epub 2015 Apr 12.; Muscat C, Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis. 1995 May;54(5): 382-5. doi:10.1136/ard.54.5.382.; Kanik KS, Yarboro CH, Naparstek Y, et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996 Jun;39(6): 1027-9. doi:10.1002/art.1780390621.; Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS. High dose intravenous immunoglobulin (IVIG) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol. 1996 Nov-Dec;14(6): 657-60.; Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec;21(12):2353-8.; https://mrj.ima-press.net/mrj/article/view/1592

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1592
https://doi.org/10.14412/1996-7012-2024-3-78-84

المؤلفون: G. M. Koilubaeva, A. M. Bolotbekova, M. T. Beishenkulov, O. N. Egorova, G. M. Tarasova, A. M. Lila, G. Suiunbay kyzy, A. T. Turatbekova, A. A. Okunova, M. A. Chukubaev, Z. E. Turdukulov, D. A. Usupbaeva, Г. М. Койлубаева, А. М. Болотбекова, М. Т. Бейшенкулов, О. Н. Егорова, Г. М. Тарасова, А. М. Лила, Г. Суйунбай кызы, А. Т. Туратбекова, А. А. Окунова, М. А. Чукубаев, З. Э. Турдукулов, Д. А. Усупбаева

المصدر: Rheumatology Science and Practice; Vol 61, No 5 (2023); 576-583 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 576-583 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: сердечно-сосудистая система, aortic regurgitation, arterial hypertension, cardiovascular system, аортальная регургитация, артериальная гипертензия

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3440/2319; Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919-929. doi:10.7326/0003-4819-120-11-199406010-00004; Johnston SL, Lock RJ, Gompels MM. Takayasu’s arteritis: A review. J Clin Pathol. 2002;55(7):481-486. doi:10.1136/jcp.55.7.481; Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu’s arteritis. Clin Exp Rheumatolog. 2011;29(Suppl 64):86-91.; Miloslavsky E, Unizony S. The heart in vasculitis. Rheum Dis Clin North Am. 2014;270(1):74-81.; Li J, Zhu M, Li M, Zheng W, Zhao J, Tian X, et al. Cause of death in Chinese Takayasu arteritis patients. Medicine (Baltimore). 2016;95(27):e4069. doi:10.1097/MD.0000000000004069; Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Corrigendum to “Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea – A nationwide, population-based study”. Int J Cardiol. 2017;238:182. doi:10.1016/j.ijcard.2017.04.013; Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al.; DCVAS Study Group. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022;81(12):1654-1660. doi:10.1136/ard2022-223482; Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: New classification. Int J Cardiol. 1996;54(Suppl):155-163. doi:10.1016/s0167-5273(96)02813-6; Chen Z, Li J, Yang Y, Li H, Zhao J, Sun F, et al. The renal artery is involved in Chinese Takayasu’s arteritis patients. Kidney Int. 2018;93(1):245-251. doi:10.1016/j.kint.2017.06.027; Quinn KA, Gribbons KB, Carette S, Cuthbertson D, Khalidi NA, Koening CL, et al. Patterns of clinical presentation in Takayasu’s arteritis. Semin Arthritis Rheum. 2020;50(4):576-581. doi:10.1016/j.semarthrit.2020.04.012; Gormezano NW, Santos MC, Okuda EM, Catani LH, Sacchetti SB. Association between rheumatic fever and Takayasu’s arteritis – Case report. Rev Bras Reumatol Engl Ed. 2016;56(2):178-180. doi:10.1016/j.rbre.2014.09.003; Sharma BK, Jain S, Sagar S. Systemic manifestations of Takayasu arteritis: The expanding spectrum. Int J Cardiol. 1996;54(Suppl):149-154. doi:10.1016/s0167-5273(96)88784-5; Sy A, Khalidi N, Dehghan N, Barra L, Carette S, Cuthbertson D, et al.; Vasculitis Clinical Research Consortium (VCRC); Canadian Vasculitis Network (CanVasc). Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016;45(4):475-482. doi:10.1016/j.semarthrit.2015.07.006; Sanchez-Alvarez C, Mertz LE, Thomas CS, Cochuyt JJ, Abril A. Demographic, clinical, and radiologic characteristics of a cohort of patients with Takayasu arteritis. Am J Med. 2019;132(5):647-651. doi:10.1016/j.amjmed.2018.12.017; Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al.; Indian Rheumatology Vasculitis (IRAVAS) group. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013;52(10):1795-1801. doi:10.1093/rheumatology/ket128; Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu’s disease). Circulation, 1978;57(1):27-35. doi:10.1161/01.cir.57.1.27; North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med, 1991;325:445-453.; Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379-1387.; Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371. doi:10.1016/j.echo.2017.01.007; Zhu WG, Lin X, Zhang W, Wang Y. Cardiac manifestations of Takayasu’s arteritis. Chin J Allergy Clin Immunol. 2011;5:217-222.; Yang L, Zhang H, Jiang X, Zou Y, Qin F, Song L, et al. Clinical manifestations and longterm outcome for patients with Takayasu arteritis in China. J Rheumatol. 2014;41(12):2439-2446. doi:10.3899/jrheum.140664; Wan J, Pan LL, Ci WP, Liao H, Wang T. Manifestations and risk factors of cardiac involvement in patients with Takayasu’s arteritis. China Med. 2015;10:1103-1107.; Li J, Sun F, Chen Z, Yang Y, Zhao J, Li M, et al. The clinical characteristics of Chinese Takayasu’s arteritis patients: a retrospective study of 411 patients over 24 years. Arthritis Res Ther. 2017;19(1):107. doi:10.1186/s13075-017-1307-z; Бородина ИЭ, Попов АА, Шардина ЛА. Предикторы кардиоваскулярных осложнений у пациентов с артериитом Такаясу: результаты ретроспективного исследования и материалов аутопсий. Медицина. 2018;2:57-68. doi:10.29234/2308-9113-2018-6-2-57-68; Teoh PC, Tan LK, Chia BL, Chao TC, Tambyah JA, Feng PH. Non-specific aorto-arteritis in Singapore with special reference to hypertension. Am Heart J. 1978;95(6):683-690. doi:10.1016/0002-8703(78)90496-9; Kwon HW, Suh YJ, Bang JS, Kwon BS, Kim GB, Bae EJ, et al. Aortic valve replacement surgery for a case of infantile Takayasu arteritis. Korean J Pediatr. 2012;55(7):254-258. doi:10.3345/kjp.2012.55.7.254; Alali WM, Alahmari SA, Alhebaishi YS, Alrashidi SA. Severe aortic regurgitation complicating Takayasu’s arteritis. Saudi Med J. 2017;38(8):863-867. doi:10.15537/smj.2017.8.12473; Matsuura K, Ogino H, Kobayashi J, Ishibashi-Ueda H, Matsuda H, Minatoya K, et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: Long-term morbidity and mortality. Circulation. 2005;112(24):3707-3712. doi:10.1161/CIRCULATIONAHA.105.535724; Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu’s arteritis. Autoimmun Rev. 2007;6(8):566-571. doi:10.1016/j.autrev.2007.04.001; Comarmond C, Cluzel P, Toledano D, Costedoat-Chalumeau N, Isnard R, Gaudric J, et al. Findings of cardiac magnetic resonance imaging in asymptomatic myocardial ischemic disease in Takayasu arteritis. Am J Cardiol. 2014;113(5):881-887. doi:10.1016/j.amjcard.2013.11.045; Kang EJ, Kim SM, Chloe YH, Lee G, Lee KN, Kim DK. Takayasu’s arteritis: Assessment of coronary arterial abnormalities with 128-section dual-source CT angiography of the coronary arteries and aorta. Radiology. 2014;270(1):74-81.; Wang EL, Sato Y, Takeichi T, Kitamura O. Sudden death of an infant with coronary involvement due to Takayasu arteritis. Cardiovasc Pathol. 2013;22(1):109-111. doi:10.1016/j.carpath.2012.05.002; Hlavatary L, Diaz F, Sung L. Takayasu’s arteritis of the coronary arteritis presenting as sudden death in a white teenager. Am J Forensic Med Pathol. 2015;36:221-223.; Tann OR, Tulloh RM, Hamilton MC. Takayasu’s disease: A review. Cardiol Young. 2008;18(3):250-259. doi:10.1017/S1047951108002060; Arabidze GG, Abugova SP, Domba GU. Non-specific aortoarteritis. Clinical course and long-term medical treatment. Inter Angiog, 1985;4:165-169.; Ueno A, Awane Y, Wakabayashi A, Shimizu K. Successfully operated obliterative brachiocephalic arteritis (Takayasu) associated with the elongated coarctation. Jpn Heart J. 1967;8(5):538-544. doi:10.1536/ihj.8.538; Чихладзе НМ, Сивакова ОА, Чазова ИЕ. Клинические проявления поражения сердечно-осудистой системы при неспецифическом аортоартериите. Системные гипертензии. 2008;5(4):22-24.; Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J. 1977;93(1):94-103. doi:10.1016/s0002-8703(77)80178-6; Koide K. Takayasu’s arteritis in Japan. Heart vessels. 1992;7(Suppl): 48-54.; Mammeri A, Guermaz R, Hatri A. Hypertension during Takayasu’s disease: An Algerian single center experience of 279 patients. Ann Cardiol Angeiol (Paris). 2017;66(3):154-158.; Ham SW, Kumar SR, Rowe VL, Weaver FA. Disease progression after initial surgical intervention for Takayasus arteritis. J Vasc Surg. 2011;54(5):1345-1351.; Qi Y, Yang L, Zhang H, Liang E, Song L, Cai J, et al. The presentation and management of hypertension in a large cohort of Takayasu arteritis. Clin Rheumatol. 2018;37(10):2781-2788. doi:10.1007/s10067-017-3947-4; De Cobelli F, Pieroni M, Esposito A, Chimenti C, Belloni E, Mellone R, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006;47(8):1649-1654. doi:10.1016/j.jacc.2005.11.067; Mavrogeni S, Dimitroulas T, Kitas GD. Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmun Rev. 2012;12(2):305-312. doi:10.1016/j.autrev.2012.05.005; Kadkhodayan A, Chareonthaitawee P, Raman SV, Cooper LT. Imaging of inflammation in unexplained cardiomyopathy. JACC Cardiovasc Imaging. 2016;9(5):603-617. doi:10.1016/j.jcmg.2016.01.010; Talwar KK, Chopra P, Narula J, Shrivastava S, Singh SK, Sharma S, et al. Myocardial involvement and its response to immunosuppressive therapy in nonspecific aortoarteritis (Takayasu’s disease) – A study by endomyocardial biopsy. Int J Cardiol. 1988;21(3):323-334. doi:10.1016/0167-5273(88)90109-x; Bechman K, Gopalan D, Nihoyannopoulos P, Mason JC. A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis. Semin Arthritis Rheum. 2017;47(2):241-246. doi:10.1016/j.semarthrit.2017.03.023; Kumar S, Subramanyan R, Mandalam KR, Rao VR, Gupta AK, Joseph S, et al. Aneurysmal form of aortoarteritis (Takayasu’s disease): Analysis of thirty cases. Clin Radiol. 1990;42(5):342-347. doi:10.1016/s0009-9260(05)82150-6; Garg J, Krishnamoorthy P. Clinical outcomes in patients with Takayasu’s arteritis: Retrospective analysis from National Inpatient Sample Database. Circulation. 2018;130:A17857.; Zheng D, Fan D, Liu L. Takayasu arteritis in China: A report of 530 cases. Heart Vessels. 1992;7(Suppl):32-36. doi:10.1007/BF01744541; Cong XL, Dai SM, Feng X, Wang ZW, Lu QS, Yuan LX, et al. Takayasu’s arteritis: Clinical features and outcomes of 125 patients in China. Clin Rheumatol. 2010;29(9):973-981. doi:10.1007/s10067-010-1496-1; Huo J, Wang B, Yu L, Gao D, Cheng R, Wang J, Zhou X, et al. Clinical characteristics and outcomes in patients with Takayasu arteritis coexisting with myocardial ischemia and neurological symptoms: A multicenter, long-term, follow-up study. Front Cardiovasc Med. 2022;9:948124. doi:10.3389/fcvm.2022.948124; https://rsp.mediar-press.net/rsp/article/view/3440

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3440
https://doi.org/10.47360/1995-4484-2023-576-583

المؤلفون: O. N. Egorova, G. M. Tarasova, G. M. Koylubaeva, A. M. Bolotbekova, I. A. Guseva, T. M. Reshetnyak, A. T. Turatbekova, G. Suyunbai kyzy, A. O. Abdykerimov, A. A. Okunova, О. Н. Егорова, Г. М. Тарасова, Г. М. Койлубаева, А. М. Болотбекова, И. А. Гусева, Т. М. Решетняк, А. Т. Туратбекова, Г. Суйунбай кызы, А. О. Абдыкеримов, А. А. Окунова

المساهمون: The article was prepared as a part of the research work (№/№ of government tasks PK 122040400024-7) and international cooperation of V.A. Nasonova Research Institute of Rheumatology (Russia) and the National Center of Cardiology and Therapy named after academician Mirsaid Mirrakhimov at the Ministry of Health of the Kyrgyz Republic (Kyrgyz Republic)., Статья подготовлена в рамках научно-исследовательской работы (№/№ государственных заданий РК 122040400024-7) и международного сотрудничества ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (Россия) и Национального центра кардиологии и терапии им. академика Мирсаида Миррахимова при Министерстве здравоохранения Кыргызской республики (Кыргызстан).

المصدر: Modern Rheumatology Journal; Том 17, № 6 (2023); 122-127 ; Современная ревматология; Том 17, № 6 (2023); 122-127 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: рекомендации EULAR 2023 г, giant cell arteritis, visualization methods, EULAR recommendations 2018, EULAR recommendations 2023, гигантоклеточный артериит, методы визуализации, рекомендации EULAR 2018 г

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1512/1428; Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi:10.1002/art.37715.; Pugh D, Karabayas M, Basu N, et al. Large-vessel vasculitis. Nat Rev Dis Primers. 2022 Jan 6;7(1):93. doi:10.1038/s41572-021-00327-5.; Stone JR, Bruneval P, Angelini A, et al. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases. Cardiovasc Pathol. 2015 Sep-Oct; 24(5):267-78. doi:10.1016/j.carpath.2015.05.001. Epub 2015 May 16.; Shima N, Nagashima T, Iwamoto M, Minota S. Comment on: retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheum Dis. 2017 Dec; 20(12):2211-2213. doi:10.1111/1756-185X.12945. Epub 2016 Aug 12.; Furuta S, Cousins C, Chaudhry A, Jayne D. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity? J Rheumatol. 2015 Feb;42(2): 300-8. doi:10.3899/jrheum.140562. Epub 2014 Nov 15.; Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi:10.1002/art.40044. Epub 2017 Mar 3.; Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017 Apr;69(4):846-853. doi:10.1002/art.40037. Epub 2017 Mar 8.; Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. doi:10.1136/annrheumdis-2017-212649. Epub 2018 Jan 22.; Maz M, Chung SA, Abril A, et al. 2021 American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Care Res (Hoboken). 2021 Aug;73(8): 1071-1087. doi:10.1002/acr.24632. Epub 2021 Jul 8.; Mackie SL, Dejaco C, Appenzeller S, et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford). 2020 Mar 1;59(3):487-494. doi:10.1093/rheumatology/kez664.; Haaversen AB, Brekke LK, Bakland G, et al. Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis. Front Med (Lausanne). 2023 Jan 6:9:1082604. doi:10.3389/fmed.2022.1082604. eCollection 2022.; Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2023 Aug 7:ard-2023-224543. doi:10.1136/ard-2023- 224543. Online ahead of print.; Bosch P, Bond M, Dejaco C, et al. Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. Ann Rheum Dis. 2023;82:124-5. doi:10.1136/annrheumdis-2023-eular.1046.; Chrysidis S, Døhn UM, Terslev L, et al. Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, nonInterventional, cohort study. The Lancet Rheumatology. 2021;3:e865–73. doi:10.1016/S2665-9913(21)00246-0.; Luqmani R, Lee E, Singh S, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016 Nov;20(90):1-238. doi:10.3310/hta20900.; Germanт G, Monti S, Ponte C, et al. The role of ultrasound in the diag-nosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):194-198. Epub 2017 Mar 29.; Li D, Lin J, Yan F. Detecting disease extent and activity of Takayasu arte-ritis using whole-body magnetic resonance angiography and vessel wallimaging as a 1-stop solution. J Comput Assist Tomogr. 2011 Jul-Aug;35(4): 468-74. doi:10.1097/RCT.0b013e 318222d698.; Bezerra Lira-Filho E, Campos O, Lazaro Andrade J, et al. Thoracic aorta evaluation in patients with takayasu's arteritis by transesophageal echocardiography. J Am Soc Echocardiogr. 2006 Jun;19(6):829-34. doi:10.1016/j.echo.2005.12.023.; Nienhuis PH, Sandovici M, Glaudemans AW, et al . Visual and semiquantitative assessment of cranial artery inflammation with FDG-PET/ CT in giant cell arteritis. Semin Arthritis Rheum. 2020 Aug;50(4):616-623. doi:10.1016/j.semarthrit.2020.04.002. Epub 2020 Jun 2.; Nielsen BD, Hansen IT, Kramer S, et al. Simple dichotomous assessment of cranial artery inflammation by conventional 18F-FDG PET/CT shows high accuracy for the diagnosis of giant cell arteritis: a case-control study. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1): 184-193. doi:10.1007/s00259-018-4106-0. Epub 2018 Jul 31.; van der Geest KSM, Treglia G, Glaudemans AWJM, et al. Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3886-3902. doi:10.1007/s00259-021-05362-8.; Yang Y, Wang Y, Lin J, et al. The diagnostic value of FDG PET/CT in Takayasu arteritis. J Nucl Cardiol. 2022 Aug;29(4):2029- 2030. doi:10.1007/s12350-020-02412-w.; Юдин ВИ. Ошибки в диагностике и результаты лечения больных неспецифическим аортоартериитом. Автореф. дисс. докт. мед. наук. Москва; 1993. С. 7-14.; Imfeld S, Aschwanden M, Rottenburger C, et al. [18F]FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: congruent or complementary imaging methods. Rheumatology (Oxford). 2020 Apr 1;59(4):772-778. doi:10.1093/rheumatology/kez362.; Nielsen BD, Hansen IT, Keller KK, et al. Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. Rheumatology (Oxford). 2020 Aug 1;59(8):2062-2073. doi:10.1093/rheumatology/kez568.; Quinn KA, Ahlman MA, Malayeri AA, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018 Aug;77(8):1165- 1171. doi:10.1136/annrheumdis-2018- 213102. Epub 2018 Apr 17.; American College of Radiology. ACR manual on contrast media. https://www.acr.org/media/ACR/Files/Clinical-Resources/ContrastMedia.pdf; Griner PF, Mayewski RJ, Mushlin AI, et al. Selection and interpretation of diagnostic tests and procedures. Ann Intern Med. 1981 Apr;94(4 Pt 2):557-92.; Fernandez-Fernandez E, Monjo-Henry I, Bonilla G, et al. False positives in the ultrasound diagnosis of giant cell arteritis: some diseases can also show the halo sign. Rheumatology (Oxford). 2020 Sep 1;59(9):2443-2447. doi:10.1093/rheumatology/kez641.; Lötscher F, Pop R, Seitz P, et al. Spectrum of Large- and medium-vessel vasculitis in adults: neoplastic, infectious, drug-induced, autoinflammatory, and primary immunodeficiency diseases. Curr Rheumatol Rep. 2022 Oct; 24(10):293-309. doi:10.1007/s11926-022-01083-5. Epub 2022 Aug 3.; Molina Collada J, Ruiz Bravo-Burguillos E, Monjo I, et al. Positive ultrasound halo sign of temporal arteries due to amyloidosis. Rheumatology (Oxford). 2019 Nov 1;58(11):2067- 2069. doi:10.1093/rheumatology/kez182.; Nielsen BD, Gormsen LC, Hansen IT, et al. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1119- 1128. doi:10.1007/s00259-018-4021-4.; Ponte C, Serafim AS, Monti S, et al. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3717-3726. doi:10.1093/rheumatology/keaa196.; Habib HM, Essa AA, Hassan AA. Color duplex ultrasonography of temporal arteries: role in diagnosis and follow-up of suspected cases of temporal arteritis. Clin Rheumatol. 2012 Feb;31(2):231-7. doi:10.1007/s10067-011-1808-0. Epub 2011 Jul 9.; Gunawardene AR, Chant H. Facial nerve injury during temporal artery biopsy. Ann R Coll Surg Engl. 2014 May;96(4):257-60. doi:10.1308/003588414X13814021679438.; Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and Polymyalgia Rheumatica. Ann Rheum Dis. 2023 Feb 24:ard-2022- 223429. doi:10.1136/ard-2022-223429. Online ahead of print.; https://mrj.ima-press.net/mrj/article/view/1512

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1512
https://doi.org/10.14412/1996-7012-2023-6-122-127

المؤلفون: O. N. Egorova, A. V. Datsina, M. V. Severinova, О. Н. Егорова, А. В. Дацина, М. В. Северинова

المساهمون: The article has been conducted within scientific topic № 1021051402790-6 as a part of the government task., Статья подготовлена в рамках научно-исследовательской работы, № государственных заданий 1021051402790-6.

المصدر: Modern Rheumatology Journal; Том 17, № 4 (2023); 42-49 ; Современная ревматология; Том 17, № 4 (2023); 42-49 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: диагностика, calciphylaxis, soft tissue calcification, diagnosis, кальцифилаксия, кальциноз мягких тканей

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1458/1383; Llamas-Velasco M, Fraga J, Sanchez-Schmidt JM, et al. Neutrophilic Infiltrates in Panniculitis: Comprehensive Review and Diagnostic Algorithm Proposal. Am J Dermatopathol. 2020 Oct;42(10):717-730. doi:10.1097/DAD.0000000000001597.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Панникулит в современной ревматологии. Терапевтический архив. 2020;92(5):33-38.; Zoller ES , Rizzo М, Harris A.Understanding calcinosis cutis. JAAPA. 2020 Nov;33(11): 25-28. doi:10.1097/01.JAA.0000718276.11292.e2.; Traineau Н, Aggarwal R, Monfort JB, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. J Am Acad Dermatol. 2020 Feb;82(2): 317-325. doi:10.1016/j.jaad.2019.07.006.; Le С, Bedocs РМ. Calcinosis Cutis. Stat-Pearls Publishing; 2023.; Bryant J, White W. A case of calcification of the arteries and obloterative endarterities, associated with hydronephrosis, in a child aged six months. Guys Hosp Rep. 1898;55:17-20.; Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology. 1962 Oct;71: 554-8. doi:10.1210/endo-71-4-554.; Sowers K, Hayden M. Calcific uremic arteriopathy: Pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev. 2010 Mar-Apr;3(2):109-21. doi:10.4161/oxim.3.2.11354.; Baby D, Upadhyay M, Joseph MD, et al. Calciphylaxis and its diagnosis: a review. J Family Med Prim Care. 2019 Sep 30;8(9): 2763-2767. doi:10.4103/jfmpc.jfmpc58819.; Elahmar Н, Feldman ВМ, Johnson SR. Management of Calcinosis Cutis in Rheumatic Diseases. J Rheumatol. 2022 Sep;49(9): 980-989. doi:10.3899/jrheum.211393. Epub 2022 May 15.; Gutierrez A Jr, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012 Mar-Apr;25(2):195-206. doi:10.1111/j.1529-8019.2012.01492.x.; Davuluri S, Lood C, Chung L. Calcinosis in systemic sclerosis. Curr Opin Rheumatol. 2022 Nov 1;34(6):319-327. doi:10.1097/BOR.0000000000000896. Epub 2022 Aug 19.; Антелава ОА, Егорова ОН, Белов БС и др. Панникулит при дерматомиозите. Научно-практическая ревматология. 2016;54(2):227-232.; Gauhar R, Wilkinson J, Harris J, et al. Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis. Scand J Rheumatol. 2016 Jul;45(4):317-20. doi:10.3109/03009742.2015.1127412. Epub 2016 Jan 26.; Cruz-Dominguez MP, Garcia-Collinot G, Saavedra MA, et al. Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis. Clin Rheumatol. 2017 Jan; 36(1):111-117. doi:10.1007/s10067-016-3412-9. Epub 2016 Oct 7.; Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005 Jun;34(6):805-12. doi:10.1016/j.semarthrit.2005.01.016.; Al Mehmadi BA, To FZ, Anderson MA, Johnson SR. Epidemiology and treatment of peripheral neuropathy in systemic sclerosis. J Rheumatol. 2021 Dec;48(12):1839-1849. doi:10.3899/jrheum.201299. Epub 2021 Jul 1.; Pai S, Hsu V. Are there risk factors for scleroderma-related calcinosis? Mod Rheumatol. 2018 May;28(3):518-522. doi:10.1080/14397595.2017.1349594. Epub 2017 Jul 19.; Ferri C, Valentini G, Cozzi F et al; Syste-mic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002 Mar;81(2): 139-53. doi:10.1097/00005792-200203000-00004.; Avouac J, Mogavero G, Guerini H, et al. Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study. Ann Rheum Dis. 2011 Apr;70(4):630-3. doi:10.1136/ard.2010.134304. Epub 2010 Dec 3.; Mierau R, Moinzadeh P, Riemekasten G, et al. Frequency of disease-associated and ot-her nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther. 2011;13(5):R172. doi:10.1186/ar3495. Epub 2011 Oct 21.; Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984 Feb;27(2):125-31. doi:10.1002/art.1780270202.; Baron M, Pope J, Robinson D, et al. Calcinosis is associated with digital ischaemia in systemic sclerosisa longitudinal study. Rheumatology (Oxford). 2016 Dec;55(12):2148-2155. doi:10.1093/rheumatology/kew313. Epub 2016 Sep 4.; Chung MP, Richardson C, Kirakossian D, et al; International Myositis Assessment; Clinical Studies Group (IMACS) Calcinosis Scientific Interest Group. Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev. 2020 Jun;19(6):102533. doi:10.1016/j.autrev.2020.102533. Epub 2020 Mar 28.; Freire V, Bazeli R, Elhai M, et al. Hand and wrist involvement in systemic sclerosis: US features. Radiology. 2013 Dec;269(3): 824-30. doi:10.1148/radiol.13121994. Epub 2013 Oct 28.; Bartoli F, Fiori G, Braschi F, et al. Calcinosis in systemic sclerosis: subsets, distribution and complications. Rheumatology (Oxford). 2016 Sep;55(9):1610-4. doi:10.1093/rheumatology/kew193. Epub 2016 May 30.; Kodumudi V, Jeha GM, Mydlo N, Kaye AD. Management of cutaneous calciphylaxis. Adv Ther. 2020 Dec;37(12):4797-4807. doi:10.1007/s12325-020-01504-w; Chang JJ. Calciphylaxis: diagnosis, pathogenesis, and treatment. Adv Skin Wound Care. 2019 May;32(5):205-215. doi:10.1097/01.ASW.0000554443.14002.13.; Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol. 2012 Apr; 148(4):455-62. doi:10.1001/archdermatol.2011.2052. Epub 2011 Dec 19.; Cucchiari D, Torregrosa JV. Calciphylaxis in patients with chronic kidney disease: a disease which is still bewildering and potentially fatal. Nefrologia. 2018 Nov-Dec;38(6): 579-86. doi:10.1016/j.nefroe.2018.09.001; Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-254. doi:10.1093/rheumatology/kew396. Epub 2016 Nov 11.; Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib - a report of two cases. J Autoimmun. 2019 Jun;100:131-136. doi:10.1016/j.jaut.2019.03.003. Epub 2019 Mar 9.; Петухова ВВ, Идрисова РВ, Снегирева ЛС и др. Первичный опухолевый (туморальный) кальциноз — редкое заболевание в практике ревматолога и ортопеда: опыт применения ингибитора интерлейкина-1 в сочетании с хирургической коррекцией. Ортопедия, травматология и восстановительная хирургия детского возраста. 2019;7(3):85-92.; Dauchez A, Souffir C, Quartier P, et al. Hyperphosphatemic familial tumoral calcinosis with galnt3 mutation: transient response to anti-interleukin-1 treatments. JBMR Plus. 2019 Mar 6;3(7):e10185. doi:10.1002/jbm4.10185; Mandelbrot DA, Santos PW, Burt RK, et al. Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation. Nephrol Dial Transpl. 2008 Aug; 23(8):2679-2684. doi:10.1093/ndt/gfn036.; Антелава ОА, Насонов ЕЛ. Современные методы оценки активности и повреждения при идиопатических воспалительных миопатиях. Научно-практическая ревматология. 2007;(1):59-62.; Berger RG, Featherstone GL, Raasch RH, et al. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1987 Jul;83(1): 72-6. doi:10.1016/0002-9343(87)90499-2.; Petri M, Orbai AM, Alarcon GS, et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012 Aug;64(8): 2677-86. doi:10.1002/art.34473.; Aggarwal R, Rider L, Ruperto N, et al. 2016 American College of Rheumatology/ European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and poly-myositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017 May;76(5):792-801. doi:10.1136/annrheumdis-2017-211400.; Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria For Systemic Sclerosis: an American College of Rheumatology / European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-55. doi:10.1136/annrheumdis-2013-204424; Maeseneer M, Stavros K, Kakkos SK, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022 Feb;63(2):184-267. doi:10.1016/j.ejvs.2021.12.024.; Bodoki L, Nagy-Vincze M, Griger Z, et al. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014 Dec;13(12):1211-9. doi:10.1016/j.autrev.2014.08.011.; Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018 Jul 26;379(4):399-400. doi:10.1056/NEJMc1807324.; Champion RH. Livedo reticularis. A review. Br J Dermatol. 1965 Apr;77:167-79. doi:10.1111/j.1365-2133.1965.tb14627.x.; Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015 Sep-Oct;6(5):315-21. doi:10.4103/2229-5178.164493.; Chiriac A, Grosu OM, Terinte C, Pertea M. Calcific uremic arteriolopathy (calciphylaxis) calls into question the validity of guidelines of diagnosis and treatment. J Dermatolog Treat. 2020 Aug;31(5):545-548. doi:10.1080/09546634.2019.1618435.; Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 201 6 Nov;27(11):3421-3429. doi:10.1681/ASN.2015091065. Epub 2016 Apr 14.; Nigwekar SU, Bloch DB, Nazarian RM, et al. Vitamin K-dependent carboxylation of matrix Gla protein influences the risk of calciphylaxis. J Am Soc Nephrol. 2017 Jun;28(6): 1717-22. doi:10.1681/ASN.2016060651.; Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007 Apr;56(4):569-79. doi:10.1016/j.jaad.2006.08.065. Epub 2006 Dec 1.; Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002 Feb 5;105(5):650-655. doi:10.1161/hc0502.102969.; Chen NX, O'Neill K, Akl NK, Moe SM. Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochem Biophys Res Commun. 2014 Jun 20;449(1): 151-156. doi:10.1016/j.bbrc.2014.05.005.; El-Azhary RA, Patzelt MT, McBane RD, et al. Calciphylaxis: a disease of pannicular thrombosis. Mayo Clin Proc. 2016 Oct;91(10): 1395-1402. doi:10.1016/j.mayocp.2016.06.026.; Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008 Mar;58(3):458-471. doi:10.1016/j.jaad.2007.12.006.; Zhang YX, Tang RN, Wang LT, Liu BC. Role of crosstalk between endothelial cells and smooth muscle cells in vascular calcification in chronic kidney disease. Cell Prolif. 2021 Mar;54(3):e12980. doi:10.1111/cpr.12980.; Noonan J, Grassia G, MacRitchie N, et al. A novel triple-cell two-dimensional model to study immune-vascular interplay in atherosclerosis. Front Immunol. 2019 Apr 24;10:849. doi:10.3389/fimmu.2019.00849. eCollection 2019.; https://mrj.ima-press.net/mrj/article/view/1458

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1458
https://doi.org/10.14412/1996-7012-2023-4-42-49

المؤلفون: O. N. Egorova, A. V. Datsina, О. Н. Егорова, А. В. Дацина

المصدر: Modern Rheumatology Journal; Том 17, № 3 (2023); 37-44 ; Современная ревматология; Том 17, № 3 (2023); 37-44 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: CT scan, abdominal pain, rheumatic diseases, differential diagnosis

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1429/1359; Wagner C, Dachman A, Ehrenpreis ED. Mesenteritis and mesenteric lipodystrophy: descriptive review of a rare condition. Clin Colon Rectal Surg. 2022 Aug 10;35(4):342-8. doi:10.1055/s-0042-1743588.; Van Putte-Katier N, van Bommel EF, Elgersma OE, et al. Mesenteric panniculitis: Prevalence, clinicoradiological presentation and 5-year follow-up. Br J Radiol. 2014 Dec; 87(1044):20140451. doi:10.1259/bjr.20140451.; Carbonell S, Melgar P, Paya A, et al. Mesenteric panniculitis of the colon. Gastroenterol Hepatol. 2014 Apr;37(4):247-51. doi:10.1016/j.gastrohep.2013.06.010.; Protin-Catteau L, Thiefin G, Barbe C, et al. Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis. Acta Radiol. 2016 Dec;57(12):1438-44. doi:10.1177/0284185116629829.; Coulier B. Mesenteric panniculitis: Part 2: Prevalence and natural course: MDCT prospective study. JBR-BTR. 2011 Sep-Oct; 94(5):241-6. doi:10.5334/jbr-btr.659.; Issa I, Baydoun H. Mesenteric panniculitis: various presentations and treatment regimens. World J Gastroenterol. 2009 Aug 14;15(30): 3827-30. doi:10.3748/wjg.15.3827.; Sharma P, Yadav S, Needham CM, et al. Sclerosing mesenteritis: A systematic review of 192 cases. Clin J Gastroenterol.2017 Apr; 10(2):103-11. doi:10.1007/s12328-017-0716-5; Jura SV. Mesenterile e scleosate. Policilinicia (Sez part). 1924;31:575.; Odgen W, Bradburn D, Rives J. Panniculitis of the mesentery. Ann Surg 1960;151:659-65.; Gu G, Wang SL, Wei XM, et al. Sclerosing mesenteritis a rare cause of abdominal pain and intra-abdominal mass. Cases. 2008 Oct 16; 1(1):242. doi:10.1186/1757-1626-1-242.; Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics. 2003 Nov-Dec;23(6):1561-7. doi:10.1148/rg.1103035010.; Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017 Jan 3;127(1):1-4. doi:10.1172/JCI92035. Epub 2017 Jan 3.; Daskalogiannaki M, Voloudaki A, Prassopoulos P, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol. 2000 Feb;174(2): 427-31. doi:10.2214/ajr.174.2.1740427.; Patel N, Saleeb S, Teplick S. General case of the day. Mesenteric panniculitis with extensive inflammatory involvement of the peritoneum and intraperitoneal structures. Radiographics. 1999 Jul-Aug;19(4):1083-5. doi:10.1148/radiographics.19.4.g99jl221083.; Kakimoto K, Inoue T, Toshina K, et al. Multiple mesenteric panniculitis as a complication of Sjцgren's Syndrome leading to ileus. Intern Med. 2016;55(2):131-4. doi:10.2169/internalmedicine.55.5407. Epub 2016 Jan 15.; Nomura S, Shimojima Y, Yoshizawa E, et al. Mesenteric panniculitis in systemic lupus erythematosus showing characteristic computed tomography findings. Lupus. 2021 Jul;30(8):1358-9. doi:10.1177/09612033211 020363. Epub 2021 May 26.; Arroyo-Avila M, Vila LM. Limited systemic sclerosis initially presenting with mesenteric panniculitis. BMJ Case Rep. 2014 Oct 17; 2014:bcr2014206961. doi:10.1136/bcr-2014-206961.; Makdsi F, Brit M. A case of sclerosing mesenteritis with rheumatoid arthritis. South Med J. 2010 Jan;103(1):96-7. doi:10.1097/SMJ.0b013e3181c47b7c.; Menendez PT, Alonso S, Alperi M, Ballina J. Mesenteric panniculitis in a patient with ankylosing spondylitis. Reumatol Clin. 2013 May-Jun;9(3):197. doi:10.1016/j.reuma.2012.10.014. Epub 2013 Mar 22.; Ter Poorten MA, Thiers BH. Systemic Weber-Christian. J Cutan Med Surg. 2000 Apr;4(2):110-2. doi:10.1177/120347540000400214.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Идиопатический лобулярный панникулит как общеклиническая проблема. Терапевтический архив 2019;91(5):49-53.; Fukuda M, Miyake T, Matsubara A, et al. Sclerosing mesenteritis mimicking IgG4-related Disease. Intern Med. 2020 Feb 15;59(4): 513-8. doi:10.2169/internalmedicine.3221-19. Epub 2019 Nov 8.; Emory TS, Monihan JM, Carr NJ, Sobin LH. Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity? Am J Surg Pathol. 1997 Apr; 21(4):392-8. doi:10.1097/00000478-199704000-00004.; Eze VN, Halligan S. Mesenteric panniculitis: a clinical conundrum. Br J Radiol. 2023 Feb; 96(1142):20211369. doi:10.1259/bjr.20211369.; Suarez Acosta С, Romero Fernandez Е. Mesenteric panniculitis: A controversial entity. Many unanswered questions. Eur J Intern Med. 2015 Dec;26(10):e67-8. doi:10.1016/j.ejim.2015.09.004.; Alsuhaimi М, Alshowaiey RA, Alsumaihi AS, Aldhafeeri SM. Mesenteric panniculitis various presentations and management: A single institute ten years, experience. Ann Med Surg (Lond). 2022 Aug;80:104203.doi:10.1016/j.amsu.2022.104203; Oztan MO, Ozdemir T, Uncel M, et al. Isolated omental panniculitis in a child with abdominal pain: case report. Arch Argent Pediatr. 2016 Dec 1;114 (6):425. doi:10.5546/aap.2016.eng.e425.; Gögebakan Ö, Osterhoff MA, Albrecht T. Mesenteric panniculitis (MP): A frequent coincidental CT finding of debatable clinical significance. Rofo. 2018 Nov;190(11):1044-52. doi:10.1055/a-0633-3558. Epub 2018 Sep 6.; Badet N, Sailley N, Briquez C, et al. Mesenteric panniculitis: still an ambiguous condition. Diagn Interv Imagin. 2015 Mar;96(3): 251-7. doi:10.1016/j.diii.2014.12.002. Epub 2015 Feb 18.; Delgado Plasencia L, Rodrнguez Ballester L, Lуpez-Tomassetti Fernandez EM, et al. Mesenteric panniculitis: experience in our center. Rev Esp Enferm Dig. 2007 May;99(5): 291-7. doi:10.4321/s1130-01082007000500010.; https://mrj.ima-press.net/mrj/article/view/1429

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1429
https://doi.org/10.14412/1996-7012-2023-3-37-44

المؤلفون: O. N. Egorova, E. N. Kharlamova, G. M. Tarasova, О. Н. Егорова, Е. Н. Харламова, Г. М. Тарасова

المساهمون: The article was prepared as part of the research work №/№ of state assignments 1021051402790-6., Статья подготовлена в рамках научно-исследовательской работы №/№ государственных заданий 1021051402790-6.

المصدر: Modern Rheumatology Journal; Том 17, № 1 (2023); 7-15 ; Современная ревматология; Том 17, № 1 (2023); 7-15 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: кокаин, local form, NK-T cell lymphoma, IgG4-related diseases, sarcoidosis, infections, cocaine, локальная форма, NK-T-клеточная лимфома, IgG4-связанные заболевания, саркоидоз, инфекции

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1382/1320; Richard AW, Gulen H, Jane CB, et al. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022 Jan;18(1):22-34. doi:10.1038/s41584-021-00718-8. Epub 2021 Dec 1.; Бекетова ТВ. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;50(6):19-28.; Robson JC, Grayson PC, Ponte C, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022 Mar;81(3):315-20. doi:10.1136/annrheumdis-2021-221795. Epub 2022 Feb 2.; Grayson PC, Ponte C, Suppiah R, et al. DCVAS Study Group2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022 Mar; 81(3):309-14. doi:10.1136/annrheumdis-2021-221794. Epub 2022 Feb 2.; Iudici M, Pagnoux C, Courvoisier DS, et al; French Vasculitis Study Group. Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology (Oxford). 2022 May 30;61(6):2464-71. doi:10.1093/rheumatology/keab719.; Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014 Nov;13(11):1121-5. doi:10.1016/j.autrev.2014.08.017. Epub 2014 Aug 20.; Pagnoux C, Stubbe M, Lifermann F, et al. Wegener's granulomatosis strictly and persistently localized to one organ is rare: assessment of 16 patients from the French Vasculitis Study Group database. J Rheumatol. 2011 Mar;38(3):475-8. doi:10.3899/jrheum.100518. Epub 2010 Dec 1.; Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010 Nov;69(11):1934-9. doi:10.1136/ard.2010.130203. Epub 2010 May 28.; Stone JH. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003 Aug;48(8):2299-309. doi:10.1002/art.11075.; Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007 May;66(5):605-17. doi:10.1136/ard.2006.062711. Epub 2006 Dec 14.; Куприянова ИН, Орлова ОЛ, Флягина ВИ. Рецидив гранулематоза с полиангиитом после отмены иммуносупрессивной терапии, осложненный стойкой утратой зрения. Русский медицинский журнал. 2018;4(I):35-40.; Anderson G, Coles ET, Crane M, et al. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992 Jun;83(302):427-38.; Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000 May;43(5):1021-32. doi:10.1002/1529-0131(200005)43:53.0.CO;2-J.; Puechal X, Iudici M, Pagnoux C, et al. French Vasculitis Study Group. Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open. 2022 Mar;8(1):e002160. doi:10.1136/rmdopen-2021-002160.; Witko-Sarsat V, Daniel S, Noёl L, Mouthon L. Neutrophils and B lymphocytes in ANCA associated vasculitis. APMIS Suppl. 2009 Jun;(127):27-31. doi:10.1111/j.1600-0463.2009.02473.x.; Preston G, Yang J, Xiao H, Falk R. Understanding the pathogenesis of ANCA: Where are we today? Cleve Clin J Med. 2002; 69 Suppl 2:SII51-4. doi:10.3949/ccjm.69.suppl_2.sii51.; Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019 Feb;15(2):91-101. doi:10.1038/s41584-018-0145-y.; Csernok E, Gross WL. Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener’s). Expert Rev Clin Immunol. 2013 Jul;9(7):641-8. doi:10.1586/1744666X.2013.811052.; Hua F, Wilde B, Dolff S, Witzke O. T-lymphocytes and disease mechanisms in Wegener's granulomatosis. Kidney Blood Press Res 2009; 32: 389–98.; Lamprecht P., Holle J., Gross W. Update on clinical, pathophysiological and therapeutic aspects in ANCA associated vasculitides. Curr Drug Discov Technol. 2009 Dec;6(4): 241-51. doi:10.2174/157016309789868994.; Лопатина ИА, Моисеев СВ, Новиков ПИ и др. Цитокиновый профиль у пациентов с гранулематозом с полиангиитом. Клиническая фармакология и терапия. 2017;(2):6-11.; Lutalo PM, D'Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). J Autoimmun. 2014 Feb-Mar;48-49:94-8. doi:10.1016/j.jaut.2014.01.028. Epub 2014 Jan 29.; Holl-Ulrich K, Reinhold-Keller E, Müller A, Feller A. Pathology of vasculitis: differential diagnosis and selected disorders. Verh Dtsch Ges Pathol. 2002;86:83-90.; Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol. 1990 Jun;14(6):555-64. doi:10.1097/00000478-199006000-00006.; Maguchi S, Fukuda S, Takizawa M. Histological findings in biopsies from patients with cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis. Auris Nasus Larynx. 2001 May;28 Suppl:S53-8. doi:10.1016/s0385-8146(01)00072-4.; Tan LT, Davagnanam I, Isa H, et al. Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement. Ophthalmology. 2014 Jun;121(6):1304-9. doi:10.1016/j.ophtha.2013.12.003. Epub 2014 Feb 20.; Ismailova DS, Abramova JV, Novikov PI, Grusha YO. Clinical features of different orbital manifestations of granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1751-6. doi:10.1007/s00417-018-4014-9. Epub 2018 May 30.; Васильев ВИ, Сокол ЕВ, Седышев СХ и др. Дифференциальная диагностика ревматических и онко-гематологических заболеваний, поражающих полость и придаточные пазухи носа. Терапевтический архив. 2014;86(5):62-72.; Rodrigo JP, Suarez C, Rinaldo A, et al. Idiopathic midline destructive disease: fact or fiction. Oral Oncol. 2005 Apr;41(4):340-8. doi:10.1016/j.oraloncology.2004.10.007.; Parker NP, Pearlman AN, Conley DB, et al. The dilemma of midline destructive lesions: a case series and diagnostic review. Am J Otolaryngol. 2010 Mar-Apr;31(2):104-9. doi:10.1016/j.amjoto.2008.11.010. Epub 2009 Mar 27.; Васильев ВИ, Седышев СХ, Городецкий ВР и др. Дифференциальная диагностика гранулематоза Вегенера с экстранодальной NK/T-клеточной лимфомой на зального типа. Терапевтический архив 2012;(7):76-81.; Tigges G, Delank KW, Blasius S, Stoll W. Nasal T-cell lymphoma as a differential diagnosis of the midline granuloma syndrome. Laryngorhinootologie. 1999 Mar;78(3):139-43. doi:10.1055/s-2007-996846.; Rosignoli M, Pezzuto RW, Galli J, D'Alatri L. Midline granuloma and Wegener's granulomatosis. Acta Otorhinolaryngol Ital. 1992;12 Suppl 38:1-46.; Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. P. 276—7.; Andreou A, Thermos G, SklavounouAndrikopoulou A. Extranodal NK/T Cell Lymphoma, Nasal Type with Palatal Involvement: A Rare Case Report and Literature Review. Head Neck Pathol. 2021 Jun;15(2): 621-627. doi:10.1007/s12105-020-01182-8. Epub 2020 Jun 25.; Hue SSS, Oon ML, Wang S, et al. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology. 2020 Jan; 52(1):111-27. doi:10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.; Strouse J, Chang HB, Dimachkie MD, et al. Extranodal NK/T cell lymphoma as a rare mimicker of GPA. Arthritis Rheumatol. 2022 Mar;74(3):474. doi:10.1002/art.41956. Epub 2022 Jan 12.; Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90. doi:10.1182/blood-2016-01-643569. Epub 2016 Mar 15.; Park S, Ko YH. Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disorders. J Dermatol. 2014 Jan;41(1): 29-39. doi:10.1111/1346-8138.12322.; Ratech H, Burke JS, Blayney DW, et al. A clinicopathologic study of malignant lymphomas of the nose, paranasal sinuses, and hard palate, including cases of lethal midline granuloma. Cancer. 1989 Dec 15;64(12):2525-31. doi:10.1002/1097-0142(19891215)64:123.0.co;2-3.; Harabuchi Y, Takahara M, Kishibe K, et al. Extranodal natural Killer/T-Cell lymphoma, nasal type: basic science and clinical progress. Front Pediatr. 2019 Apr 16;7:141. doi:10.3389/fped.2019.00141. eCollection 2019.; Tamoto Y, Ishida R, Shiogama K, et al. Extranodal NK/T-cell Lymphoma, Nasal Type Accompanied by PR3-ANCA-associated Glomerulonephritis. Intern Med. 2017;56(15):2007-2012. doi:10.2169/internalmedicine.56.8365. Epub 2017 Aug 1.; Wallace ZS, Naden RP, Chari S, et al; American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020 Jan;72(1): 7-19. doi:10.1002/art.41120. Epub 2019 Dec 2.; Michailidou D, Schwartz DM, Mustelin T, Hughes GC. Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy. Front Immunol. 2021 Jul 7;12: 693192. doi:10.3389/fimmu.2021.693192. eCollection 2021.; Abbass K, Krug H. Granulomatosis with polyangiitis in a patient with biopsy-proven IgG4-related pulmonary disease and coincident small cell lung cancer. BMJ Case Rep. 2019 Mar 14;12(3):e226280. doi:10.1136/bcr-2018-226280.; Della-Torre E, Lanzillotta M, Campochiaro C, et al. Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literature. Medicine (Baltimore). 2016 Aug;95(34):e4633. doi:10.1097/MD.0000000000004633.; Martin-Nares E, Hernandez-Molina G. What is the meaning of ANCA positivity in IgG4-related disease? Rheumatology (Oxford). 2021 Aug 2;60(8):3845-50. doi:10.1093/rheumatology/keab124.; Cruz AAV, Camacho MAB, Cunha BS, et al. Plasma cell IgG4 positivity in orbital biopsies of non-IgG4-related conditions. Saudi J Ophthalmol. 2021 Nov 17;35(3):193-7. doi:10.4103/SJOPT.SJOPT_91_21. eCollection 2021 Jul-Sep.; Chang SY, Keogh KA, Lewis JE, et al. IgG4-positive plasma cells in granulomatosis with polyangiitis (Wegener’s): a clinicopathologic and immunohistochemical study on 43 granulomatosis with polyangiitis and 20 control cases. Hum Pathol. 2013 Nov;44(11): 2432-7. doi:10.1016/j.humpath.2013.05.023. Epub 2013 Aug 30.; Kawashima H, Utsugi A, Shibamiya A, et al. Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: case series and review of literature. Immunol Res. 2019 Feb;67(1):99-107. doi:10.1007/s12026-019-9070-7.; Faz-Munoz D, Hinojosa-Azaola A, Mejia-Vilet JM, et al. ANCA-associated vasculitis and IgG4-related disease overlap syndrome: a case report and literature review. Immunol Res. 2022 Aug;70(4):550-9. doi:10.1007/s12026-022-09279-8. Epub 2022 Apr 21.; Salah S, Abad S, Monnet D, Brezin AP. Sarcoidosis. J Fr Ophtalmol. 2018 Dec;41(10): e451-e467. doi:10.1016/j.jfo.2018.10.002. Epub 2018 Nov 16.; Lynch JP 3rd. Neurosarcoidosis: how good are the diagnostic tests? J Neuroophthalmol. 2003 Sep;23(3):187-9. doi:10.1097/00041327-200309000-00001.; White ES, Lynch JP 3rd. Sarcoidosis involving multiple systems: diagnostic and therapeutic challenges. Chest. 2001 May;119(5): 1593-7. doi:10.1378/chest.119.5.1593.; Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997 Apr 24;336(17): 1224-34. doi:10.1056/NEJM199704243361706.; Thomas KW, Hunninghake GW. Sarcoidosis. JAMA. 2003 Jun 25;289(24):3300-3. doi:10.1001/jama.289.24.3300.; Hu X, Zou L, Wang S, et al. Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis. Biomolecules. 2022 Sep 30;12(10):1400. doi:10.3390/biom12101400.; Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haematol. 1997 Nov;99(2):331-6. doi:10.1046/j.1365-2141.1997.3983214.x.; Cansu DÜ, Özbülbül NI, Akyol G, et al. Do pulmonary findings of granulomatosis with polyangiitis respond to anti-tuberculosis treatment? Rheumatol Int. 2018 Jun;38(6): 1131-1138. doi:10.1007/s00296-018-4027-z. Epub 2018 Apr 9.; Gunawan H, Lamsu G, Achdiat PA, et al. A rare case of multiple lupus vulgaris in a multifocal tuberculosis pediatric patient. Int J Mycobacteriol. 2019 Apr-Jun;8(2):205-7. doi:10.4103/ijmy.ijmy_33_19.; De Pontual L, Ovetchkine PH, Rodriguez D, et al. Rhinoscleroma: a French national retrospective study of epidemiological and clinical features. Clin Infect Dis. 2008 Dec 1; 47(11):1396-402. doi:10.1086/592966.; Ahmed AR, El-Badawy ZH, Mohamed IR, Abdelhameed WA. Rhinoscleroma: a detailed histopathological diagnostic insight. Int J Clin Exp Pathol. 2015 Jul 1;8(7):8438-45. eCollection 2015.; Cornely OA, Alastruey-Izquierdo A, Arenz D, et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 Dec;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3. Epub 2019 Nov 5.; Montone KT. Infectious diseases of the head and neck: a review. Am J Clin Pathol. 2007 Jul;128(1):35-67. doi:10.1309/6BBT12WGNK77N4EH.; Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008 Aug 15; 47(4):503-9. doi:10.1086/590004.; Vinay K, Khullar G, Yadav S, et al. Granulomatous Invasive Aspergillosis of Paranasal Sinuses Masquerading as Actinomycosis and Review of Published Literature. Mycopathologia. 2014 Apr;177(3-4):179-85. doi:10.1007/s11046-014-9732-x. Epub 2014 Feb 26.; Lehur AC, Zielinski M, Pluvy J, et al. Case of disseminated histoplasmosis in a HIV-infected patient revealed by nasal involvement with maxillary osteolysis. BMC Infect Dis. 2017 May 5;17(1):328. doi:10.1186/s12879-017-2419-4.; Bakhshaee M, Khadivi E, Naseri Sadr M, Esmatinia F. Nasal septum perforation due to methamphetamine abuse. Iran J Otorhinolaryngol. 2013 Winter;25(70):53-6.; Stahelin L, de Magalhгes Souza Fialho SC, Neves FS, et al. Cocaineinduced midline destruction lesions with positive ANCA test, mimicking Wegener’s granulomatosis. Rev Bras Reumatol. 2012 May-Jun;52(3):431-7.; Trimarchi M, Bertazzoni G, Bussi M. Cocaine induced midline destructive lesions. Rhinology. 2014 Jun;52(2):104-11. doi:10.4193/Rhino13.112.; Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004 Sep;50(9):2954-65. doi:10.1002/art.20479.; Mirzaei A, Zabihiyeganeh M, Haqiqi A. Differentiation of Cocaine-Induced Midline Destructive Lesions from ANCA-Associated Vasculitis. Iran J Otorhinolaryngol. 2018 Sep; 30(100):309-13.; https://mrj.ima-press.net/mrj/article/view/1382

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1382
https://doi.org/10.14412/1996-7012-2023-1-7-15

المؤلفون: G. M. Koilubaeva, A. M. Bolotbekova, O. N. Egorova, A. T. Turatbekova, G. M. Tarasova, G. Suyunbai kyzy, M. A. Chukubaev, Z. E. Turdukulov, D. A. Usupbaeva, Г. М. Койлубаева, А. М. Болотбекова, О. Н. Егорова, А. Т. Туратбекова, Г. М. Тарасова, Г. Суйунбай кызы, М. А. Чукубаев, З. Э. Турдукулов, Д. А. Усупбаева

المصدر: Modern Rheumatology Journal; Том 16, № 5 (2022); 38-45 ; Современная ревматология; Том 16, № 5 (2022); 38-45 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: томография, activity, aneurysm, monitoring, stenosis, occlusion, ultrasonic dopplerography, tomography, активность, аневризма, мониторинг, стеноз, окклюзия, ультразвуковая допплерография

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1343/1284; Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994 Jun 1;120(11):919-29. doi:10.7326/0003-4819-120-11-199406010-00004.; Watts R, Al-Taiar A, Mooney J, et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009 Aug;48(8): 1008-11. doi:10.1093/rheumatology/kep153. Epub 2009 Jun 19.; Zaldivar Villon ML, de la Rocha JA, Espinoza LR. Takayasu arteritis: recent developments. Curr Rheumatol Rep 2019; 21: 45.; Toshihiko N. Current status of large and small vessel vasculitis in Japan. Int J Cardiol. 1996 Aug;54 Suppl:S91-8. doi:10.1016/s0167-5273(96)88777-8.; Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. Int J Cardiol. 1998 Oct 1;66 Suppl 1:S85-90; discussion S91. doi:10.1016/s0167-5273(98)00155-7.; Cong X, Dai S, Feng X, et al. Takayasu’s arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol. 2010 Sep; 29(9):973-81. doi:10.1007/s10067-010-1496-1. Epub 2010 Jun 30.; Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in takayasu arteritis. Ann Intern Med. 2011 Oct 4;155(7):425-33. doi:10.7326/0003-4819-155-7-201110040-00005.; Ishihara T, Haraguchi G, Kamiishi T, et al. Sensitive assessment of activity of Takayasu’s arteritis by pentraxin 3, a new biomarker. J Am Coll Cardiol. 2011 Apr 19;57(16):1712-3. doi:10.1016/j.jacc.2010.10.058.; Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayas, s arteritis. Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S86-91. Epub 2011 May 11.; Sager S, Yilmaz S, Ozhan M, et al. F-18 Fdg PET/CT findings of a patient with Takayasu arteritis before and after therapy. Mol Imaging Radionucl Ther. 2012 Apr;21(1):32-4. doi:10.4274/Mirt.021896. Epub 2012 Apr 1.; Cheng Y, Lv N, Wang Z, et al. 18-FDGPET in assessing disease activity in Takayasu arteritis: a meta-analysis. Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S22-7. Epub 2013 Feb 25.; Papa M, De Cobelli F, Baldissera E, et al. Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. AJR Am J Roentgenol. 2012 Mar;198(3):W279-84. doi:10.2214/AJR.11.7360.; Schmidt WA. Imaging in vasculitis. Best Pract Res Clin Rheumatol. 2013 Feb;27(1): 107-18. doi:10.1016/j.berh.2013.01.001.; Zhu FP, Luo S, Wang ZJ, et al. Takayasu arteritis: imaging spectrum at multidetector CT angiography. Br J Radiol. 2012 Dec;85 (1020):e1282-92. doi:10.1259/bjr/25536451.; Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8):1129-34. doi:10.1002/art.1780330811.; Sharma BK, Jain S, Suri S, et al. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996 Aug;54 Suppl:S141-7. doi:10.1016/s0167-5273(96)88783-3.; Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013 Oct;52(10):1795-801. doi:10.1093/rheumatology/ket128. Epub 2013 Apr 16.; Zoghbi WA , Adams D , Bonow RO . Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the american society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017Apr;30(4):303-71. doi:10.1016/j.echo.2017.01.007. Epub 2017 Mar 14.; Barnett HJM, Taylor DW, Haynes RB, et al; North American Symptomatic Carotid Endar-erectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med. 1991 Aug 15;325(7):445-53. doi:10.1056/NEJM199108153250701.; Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998 May 9;351(9113): 1379-87.; Hata A, Noda M, Moriwaki R, et al. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol. 1996 Aug;54 Suppl:S155-63. doi:10.1016/s0167-5273(96)02813-6.; Jefferson R, Roberts MD. Takayasu Arteritis Differential Diagnoses. Medscape-2016. http://emedicine.medscape.com/article/332378-differential.; Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu’s disease). Circulation. 1978 Jan;57(1): 27-35. doi:10.1161/01.cir.57.1.27.; Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol. 1998 Oct 1;66 Suppl 1:S191-4; discussion S195. doi:10.1016/s0167-5273(98)00181-8.; Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in takayasu arteritis. Ann Intern Med. 2011 Oct 4; 155(7):425-33. doi:10.7326/0003-4819-155-7-201110040-00005.; Moriwaki R, Numano F. Takayasu arteritis: follow-up studies for 20 years. Heart Vessels Suppl. 1992;7:138-45. doi:10.1007/BF01744560.; Cieslik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012 Mar;45(2):119-28. doi:10.3109/08916934.2011.611549. Epub 2011 Oct 11.; Eichhorn J, Sima D, Thiele B, et al. Antiendothelial cell antibodies in Takayasu arteritis. Circulation. 1996 Nov 15;94(10):2396-401. doi:10.1161/01.cir.94.10.2396.; Wang H, Ma J, Wu Q, et al. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg. 2011 Jan; 53(1):174-80. doi:10.1016/j.jvs.2010.06.173. Epub 2010 Sep 15.; Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007 Mar;56(3):1000-9. doi:10.1002/art.22404.; Schneeweis C, Schnackenburg B, Stuber M, et al. Delayed contrast-enhanced MRI of the coronary artery wall in takayasu arteritis. PLoS One. 2012;7(12):e50655. doi:10.1371/journal.pone.0050655. Epub 2012 Dec 7.; Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging. 2000 May;11(5):481-7. doi:10.1002/(sici)1522-2586(200005)11:53.0.co;2-4.; Eshet Y, Pauzner R, Goitein O, et al. The limited role of MRI in long-term followup of patients with Takayasu’s arteritis. Autoimmun Rev. 2011 Dec;11(2):132-6. doi:10.1016/j.autrev.2011.09.002. Epub 2011 Sep 17.; Yadav MK. Takayasu arteritis: clinical and CT-angiography profile of 25 patients and a brief review of literature. Indian Heart J. 2007 Nov-Dec;59(6):468-74.; Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):318-23. doi:10.1136/ard.2008.088351. Epub 2008 Apr 15.; https://mrj.ima-press.net/mrj/article/view/1343

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1343
https://doi.org/10.14412/1996-7012-2022-5-38-45

المؤلفون: B. S. Belov, O. N. Egorova, G. M. Tarasova, N. V. Muravieva, Б. С. Белов, О. Н. Егорова, Г. М. Тарасова, Н. В. Муравьева

المصدر: Modern Rheumatology Journal; Том 16, № 5 (2022); 75-81 ; Современная ревматология; Том 16, № 5 (2022); 75-81 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: профилактика, vasculitis associated with antineutrophil cytoplasmic antibodies, comorbid infections, pneumocystis pneumonia, prevention, васкулиты, ассоциированные с антинейтрофильными цитоплазматическими антителами, коморбидные инфекции, пневмоцистная пневмония

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1350/1290; Насонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 616 с.; Theofilis P, Vordoni A, Koukoulaki M, et al. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022 May;42(5): 759-70. doi:10.1007/s00296-022-05100-9. Epub 2022 Feb 14.; Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996 Jul 4;335(1):16-20. doi:10.1056/NEJM199607043350103.; Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2021 Aug 2;60(8): 3553-64. doi:10.1093/rheumatology/keab267.; Van Gool IC, Kers J, Bakker JA, et al. Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clin Rheumatol. 2022 Jun 23. doi:10.1007/s10067-022-06240-w. Online ahead of print.; Huan G, Yang G, Xiao-Yu Q, et al. Antineutrophil cytoplasmic antibodies in Chinese patients with tuberculosis. Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):475-8. doi:10.1590/0037-8682-0400-2017.; Choi H, Park YB, Song J, Lee SW. Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Z Rheumatol. 2021 Apr 27. doi:10.1007/s00393-021-00998-1. Online ahead of print.; Söderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016 Jun 30;7:256. doi:10.3389/fimmu.2016.00256.; Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel). 2016 Mar;1(4): 205-15. doi:10.1159/000442323. Epub 2015 Dec 3.; Lizarraga KJ, Florindez JA, Daftarian P, et al. Anti-GBM disease and ANCA during dengue infection. Clin Nephrol. 2015 Feb; 83(2):104-10. doi:10.5414/CN108217.; Asano S, Mizuno S, Okachi S, et al. Antineutrophil Cytoplasmic Antibody-associated Vasculitis Superimposed on Infection-related Glomerulonephritis Secondary to Pulmonary Mycobacterium avium Complex Infection. Intern Med. 2016;55(17):2439-45. doi:10.2169/internalmedicine.55.6588. Epub 2016 Sep 1.; Addy C, Doran G, Jones AL, et al. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report. BMC Pulm Med. 2018 Nov 19;18(1):170. doi:10.1186/s12890-018-0732-3.; Hashimoto S, Aizawa T, Watanabe S, et al. Osteomyelitis-related glomerulonephritis with myeloperoxidase-antineutrophil cytoplasmic antibody positivity. Pediatr Int. 2020 Feb; 62(2):236-8. doi:10.1111/ped.14080.; Sugino H, Sawada Y, Nakamura M. IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int J Mol Sci. 2021 Jul 14;22(14):7538. doi:10.3390/ijms22147538.; Абдурахманов ДТ, Розина ТП, Новиков ПИ. HBV-ассоциированный узелковый полиартериит. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2012;(3):67-71.; Семенкова ЕН. Системные некротизирующие васкулиты. Москва: Русский врач; 2001. 96 с.; Игнатова ТМ, Козловская ЛВ, Гордовская НБ, и др. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения. Терапевтический архив. 2017:(5):45-62.; Vega LE, Espinoza LR. Vasculitides in HIV Infection. Curr Rheumatol Rep. 2020 Aug 26;22(10):60. doi:10.1007/s11926-020-00945-0.; Vega LE, Espinoza LR. Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in the pre- and post-HAART eras. Clin Rheumatol. 2020 Sep; 39(9):2515-22. doi:10.1007/s10067-020-05082-8. Epub 2020 Apr 15.; Giryes S, Bragazzi NL, Bridgewood C, et al. COVID-19 Vasculitis and vasculopathyDistinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol. 2022 May;44(3):375-90. doi:10.1007/s00281-022-00928-6. Epub 2022 Apr 12.; Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020 Jun; 46(6):1105-8. doi:10.1007/s00134-020-06059-6. Epub 2020 Apr 28.; Брегель ЛВ, Костик ММ, Фелль ЛЗ и др. Болезнь Кавасаки и мультисистемный воспалительный синдром при инфекции COVID-19 у детей. Педиатрия им. Г.Н. Сперанского. 2020;(6):209-19.; Patel P, DeCuir J, Abrams J, et al. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw Open. 2021 Sep 1;4(9):e2126456. doi:10.1001/jamanetworkopen.2021.26456.; Fabi M, Filice E, Biagi C, et al. Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area. Viruses. 2021 Oct 7;13(10): 2022. doi:10.3390/v13102022.; Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/ CT study. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1460-6. doi:10.1007/s00259-020-05084-3.; Morris D, Patel K, Rahimi O, et al. ANCA vasculitis: A manifestation of PostCovid-19 Syndrome. Respir Med Case Rep. 2021;34:101549. doi:10.1016/j.rmcr.2021.101549. Epub 2021 Nov 11.; Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov; 3(11):e743-e744. doi:10.1016/S2665-9913(21)00309-X.; Nappi E, De Santis M, Paoletti G, et al. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine. Vaccines (Basel). 2022 May 3;10(5):716. doi:10.3390/vaccines10050716.; Al-Yafeai Z, Horn BJM, Terraccaine W, et al. A Case of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Post COVID-19 Vaccination. Cureus. 2022 Mar 14;14(3):e23162. doi:10.7759/cureus.23162.; Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011 Jan;63(1):257-66. doi:10.1002/art.27763.; Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012 Nov;64(11):3770-8. doi:10.1002/art.34584.; Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009 May;68(5):658-63. doi:10.1136/ard.2008.088302.; Aasarød K, Iversen BM, Hammerstrøm J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant. 2000 May;15(5): 611-8. doi:10.1093/ndt/15.5.611.; Bligny D, Mahr A, Toumelin PL, et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004 Feb 15;51(1):83-91. doi:10.1002/art.20082.; Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018 Jun 14;19(1):138. doi:10.1186/s12882-018-0933-2.; Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015 Mar;45(3):346-68. doi:10.1111/eci.12410.; Jung M, Barra L. Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a metaanalysis. Clin Exp Rheumatol. 2018 Mar-Apr; 36 Suppl 111(2):129-34.; Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133; Segelmark L, Flores-Suarez L, Mohammad A. Severe infections in patients with ANCA-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2021 Dec 24;61(1):205-12. doi:10.1093/rheumatology/keab293.; Odler B, Windpessl M, Krall M, et al. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Front Immunol. 2021 Oct 29;12:760708. doi:10.3389/fimmu.2021.760708. eCollection 2021.; Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022 Feb;60(2):97-105. doi:10.5414/CP204053.; Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021 Jun 1;325(21):2178-87. doi:10.1001/jama.2021.6615.; Godeau B, Mainardi JL, Roudot-Thoraval F, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis. Ann Rheum Dis. 1995 Dec; 54(12):991-4.; Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with wegener’s granulomatosis. Am J Respir Crit Care Med. 1995 Mar;151 (3 Pt 1):795-9. doi:10.1164/ajrccm/151.3_Pt_1.795.; Falagas ME, Manta KG, Betsi GI, et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumatol. 2007 May;26(5): 663-70. doi:10.1007/s10067-006-0441-9. Epub 2006 Dec 21.; Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014 Dec;127(12):1242.e11- 7. doi:10.1016/j.amjmed.2014.07.010. Epub 2014 Jul 21.; Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006 Jun;12(3):114-7. doi:10.1097/01.rhu.0000221794.24431.36.; Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014 Dec; 34(12):1765-71. doi:10.1007/s00296-014-3073-4. Epub 2014 Jun 20.; Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener’s granulomatosis. Arthritis Rheum. 1997 Dec;40(12):2187-98. doi:10.1002/art.1780401213.; Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi:10.1056/NEJMoa0909169.; Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013 Aug 1;369(5):417-27. doi:10.1056/NEJMoa1213277.; Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014 Nov 6;371(19):1771-80. doi:10.1056/NEJMoa1404231.; Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi:10.1002/art.41773. Epub 2021 Jul 8.; Chung JB, Armstrong K, Schwartz S, et al. Cost-effectiveness of prophylaxis against pneumocystis carinii pneumonia in patients with wegener’s granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum. 2000 Aug;43(8):1841-8. doi:10.1002/1529-0131(200008)43:83.0.CO;2-Q.; Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-e864. doi:10.1016/S2665-9913(21)00316-7. Epub 2021 Nov 5.; Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022 May;81(5):695-709. doi:10.1136/annrheumdis-2021-221490. Epub 2021 Dec 31.; David R, Hanna P, Lee K, Ritchie A. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients. Nephrology (Carlton). 2022 Jan; 27(1):109-10. doi:10.1111/nep.13993. Epub 2021 Nov 9.; Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021 Oct 28;9(10): e05032. doi:10.1002/ccr3.5032. eCollection 2021 Oct.; Dharia T, Venkatachalam S, Baker JF, et al. Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care Res (Hoboken). 2022 May;74(5):733-40. doi:10.1002/acr.24837.; Chen YX, Yu HJ, Zhang W, et al. Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodiesassociated renal vasculitis: a 10-year retrospective study. Kidney Blood Press Res. 2008; 31(5):343-9. doi:10.1159/000165117. Epub 2008 Oct 23.; Itabashi M, Takei T, Yabuki Y, et al. Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115(1):c21-7. doi:10.1159/000286346. Epub 2010 Feb 19.; Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCAassociated vasculitis. 2011 Mar;70(3):488-94. doi:10.1136/ard.2010.137778.; https://mrj.ima-press.net/mrj/article/view/1350

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1350
https://doi.org/10.14412/1996-7012-2022-5-75-81

المؤلفون: M. Yu. Krylov, O. N. Egorova, N. V. Konovalova, D. A. Varlamov, М. Ю. Крылов, О. Н. Егорова, Н. В. Коновалова, Д. А. Варламов

المساهمون: The investigation has been conducted within scientific topic "Innovative technologies for the diagnosis and treatment of systemic diseases of the connective tissue" (IKBRS 0397-2020-0006)., Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 16, № 4 (2022); 21-26 ; Современная ревматология; Том 16, № 4 (2022); 21-26 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: ген STAT4, erythema nodosum, idiopathic lobular panniculitis, polymorphisms, SAA1 gene, CRP gene, STAT4 gene, узловатая эритема, идиопатический лобулярный панникулит, полиморфизмы, ген SAA1, ген CRP

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1318/1264; Molina-Ruiz AM, Requena L. Erythema nodosum. Med Clin (Barc). 2016;147(2):81-6. doi:10.1016/j.medcli.2016.03.038; Mert A, Kumbasar H, Ozaras R, et al. Erythema nodosum: an evaluation of 100 cases. Clin Exp Rheumatol. Jul-Aug 2007; 25(4):563-70.; Cox NH, Jorizzo JL, Bourke JF, Savage COS. Vasculitis, Neutrophilic Dermatoses and Related Disorders. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th edition. Vol. 1. Wiley; 2010. P. 82-7.; Elkayam O, Caspi D, Segal R, et al. Familial erythema nodosum. Arthritis Rheum. 1991 Sep;34(9):1177-9. doi:10.1002/art.1780340915.; Labunski S, Posern G, Ludwig S, et al. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol. Jan-Feb 2001;81(1):18-21. doi:10.1080/00015550116912.; Amoli MM, Ollier WER, Lueiro M, et al. Lack of association between ICAM-1 gene polymorphisms and biopsy-proven erythema nodosum. J Rheumatol. 2004 Feb;31(2):403-5.; Zheng W, Song W, Wu Q, et al. Analysis of the clinical characteristics of thirteen patients with Weber–Christian panniculitis. Clin Rheumatol. 2019 Dec;38(12):3635-41. doi:10.1007/s10067-019-04722-y. Epub 2019 Aug 12.; Akdis AC, Kilicturgay K, Helvaci S, et al. Immunological evaluation of erythema nodosum in tularaemia. Br J Dermatol. 1993 Sep; 129(3):275-9. doi:10.1111/j.1365-2133.1993.tb11846.x.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Идиопатический лобулярный панникулит как общеклиническая проблема. Терапевтический архив. 2019;91(5):49-53.; Сахарова КВ, Черкасова МВ, Эрдес ШФ. Сывороточный амилоид А как маркер активности анкилозирующего спондилита. Современная ревматология. 2021;15(6):72-5. doi:10.14412/1996-7012-2021-6-72-75.; Hwang YG, Balasubramani GK, Metes ID, et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016 May 17;18(1):108. doi:10.1186/s13075-016-1009-y.; Sun L, Ye RD. Serum Amyloid A1: Structure, Function and Gene Polymorphism. Gene. 2016 May 25;583(1):48-57. doi:10.1016/j.gene.2016.02.044. Epub 2016 Mar 3.; Крылов МЮ, Егорова ОН, Белов БС. Генетические аспекты панникулитов в российской популяции (пилотное исследование). Научно-практическая ревматология. 2016;54(5):553-6.; De Simone C, Caldarola G, Scaldaferri F, et al. Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. Int J Dermatol. 2016 May; 55(5):e289-94. doi:10.1111/ijd.13212. Epub 2016 Feb 24.; Frucht DM, Aringer M, Galon J, et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol. 2000 May 1;164(9):4659-64. doi:10.4049/jimmunol.164.9.4659.; Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004 Dec;202:139-56. doi:10.1111/j.0105-2896.2004.00211.x.; https://mrj.ima-press.net/mrj/article/view/1318

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1318
https://doi.org/10.14412/1996-7012-2022-4-21-26

المؤلفون: I. D. Musatov, S. G. Radenska-Lopovok, O. N. Egorova, A. A. Kolomeichuk, И. Д. Мусатов, С. Г. Раденска-Лоповок, О. Н. Егорова, А. А. Коломейчук

المساهمون: The investigation has been conducted within scientific topic №0397-2020-0006 «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases»., Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 16, № 1 (2022); 84-90 ; Современная ревматология; Том 16, № 1 (2022); 84-90 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: иммуногистохимия, lupus panniculitis, dermatomyositis, histology, immunohistochemistry, люпус-панникулит, дерматомиозит, гистология

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1257/1215; Вербенко ЕВ. Спонтанный панникулит. Вкн: Скрипкин ЮК, редактор. Кожные и венерические болезни. Руководство для врачей. Москва: Медицина; 1995. С. 399-410.; Diaz CC, Borghi S, Weyers W. Panniculitis: definition of terms and diagnostic strategy. Am J Dermatopathol. 2000 Dec;22(6):530-49. doi:10.1097/00000372-200012000-00009.; Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001 Aug;45(2):163-83; quiz 184-6. doi:10.1067/mjd.2001.114736.; Requena L, Sanchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4. doi:10.1067/mjd.2001.114735.; Wick MR. Panniculitis: A summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi:10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.; Caputo V, Rongioletti F. Panniculitis in the setting of dermato/rheumatologic diseases. G Ital Dermatol Venereol. 2018 Apr;153(2): 194-207. doi:10.23736/S0392-0488.17.05845-X. Epub 2017 Dec 15.; Егорова ОН, Белов БС. Панникулиты в практике дерматовенеролога и интерниста. Consilium Medicum. 2020;22(7):78-83.; Elder DE, Elenitsas R, Rosenbach M, et al. Lever’s histopathology of the skin. 11th edition. Philadelphia : Wolters Kluwer; 2014. P. 952-1009.; Hansen CB, Callen JP. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther. Jul-Aug 2010;23(4):341-9. doi:10.1111/j.1529-8019.2010.01334.x.; Binesh VG, Krishnan J, Asokan N, Ajithkumar K. Systemic sclerosis presenting as lobular panniculitis. Indian Dermatol Online J. 2012 Sep;3(3):222-4. doi:10.4103/2229-5178.101830.; Hasegawa A, Shimomura Y, Kibune N, et al. Panniculitis as the initial manifestation of dermatomyositis with anti-MDA5 antibody. Clin Exp Dermatol. 2017 Jul;42(5):551-3. doi:10.1111/ced.13128. Epub 2017 May 22.; Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5): 536-48.; Velter C, Lipsker D. Cutaneous panniculitis. Rev Med Interne. 2016 Nov;37(11):743-50. doi:10.1016/j.revmed.2016.05.008. Epub 2016 Jun 16.; Раденска-Лоповок СГ, Егорова ОН, Белов БС и др. Идиопатический лобулярный панникулит: клинико-морфологические корреляции. Архив патологии. 2019; 81(3):37-44.; Lin F, Prichard J. Handbook of practical immunohistochemistry: Frequently asked questions. New York: Springer Science+ Business Media; 2015. P. 17-31.; Winkelmann RK, Peters MS. Lupus panniculitis. Dermatology update. New York: Elsevier; 1982. P. 135-52.; Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol. 1999 Jan;26(1):68-72.; Sudhakar P, Shah GV, Saponara F, et al. Central retinal artery occlusion secondary to orbital inflammation in lupus erythematosus profundus. J Neuroophthalmol. 2012 Mar;32(1): 93-4. doi:10.1097/WNO.0b013e31823f8548.; Lueangarun S, Subpayasarn U, Tempark T. Distinctive lupus panniculitis of scalp with linear alopecia along Blaschko's lines: a review of the literature. Int J Dermatol. 2019 Feb; 58(2):144-50. doi:10.1111/ijd.14155. Epub 2018 Aug 3.; Navarro-Triviсo FJ, Ortego Centeno N. Linear lupus panniculitis of the scalp with good response to thalidomide. Lupus. 2019 Oct;28(11):1380-2. doi:10.1177/0961203319873703. Epub 2019 Sep 10.; Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: A Retrospective Review of 61 Patients. JAMA Dermatol. 2020 Nov 1;156(11):1264-6. doi:10.1001/jamadermatol.2020.2797.; Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018 Apr; 153(2):216-29. doi:10.23736/S0392-0488.18.05929-1. Epub 2018 Jan 24.; Fraga J, Garcнa-Dнez A. Lupus erythematosus panniculitis. Dermatol Clin. 2008 Oct; 26(4):453-63, vi. doi:10.1016/j.det.2008.06.002.; Tuffanelli DL. Lupus erythematosus (panniculitis) profundus: a classic revisited commentary and report of 22 cases. Hawaii Med J. 1982 Nov;41(11):394-7.; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. С. 113-36.; Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus Ery-thematosus Collaborating Clinics. American College of Rheumatology index for systemic lupus erythematosus international comparison. J Rheumatol.2000 Feb;27(2):373-6.; Peters MS, Su WP. Eosinophils in lupus panniculitis and morphea profunda. J Cutan Pathol. 1991 Jun;18(3):189-92. doi:10.1111/j.1600-0560.1991.tb00151.x.; Gonzalez-Cruz C, Aparicio Espaсol G, Ferrer Fаbrega B, et al. Lupus panniculitis: Clinicopathological features of a series of 12 patients. Med Clin (Barc). 2018 Dec 14; 151(11):444-9. doi:10.1016/j.medcli.2018.06.024. Epub 2018 Aug 25.; Wang T, Li X, Liu YH, et al. Lupus erythematosus panniculitis: clinical and histopathological analysis of 22 cases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Oct;33(5):525-8.; Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol. 2005 Jul;32(6):396-404. doi:10.1111/j.0303-6987.2005.00351.x.; Park HS, Choi JW, Kim BK, Cho KH. Lupus erythematosus panniculitis: clinicopathological, immunophenotypic, and molecular studies. Am J Dermatopathol. 2010 Feb;32(1): 24-30. doi:10.1097/DAD.0b013e3181b4a5ec.; Лила АМ, Мазуров ВИ, Лапин СВ и др. Современные возможности ранней диагностики системной красной волчанки. Современная ревматология. 2018;12(3):34-9.; Mysorekar VV, Sumathy TK, Shyam Prasad AL. Role of direct immunofluorescence in dermatological disorders. Indian Dermatol Online J. May-Jun 2015;6(3):172-80. doi:10.4103/2229-5178.156386.; Sontheimer RD, Gilliam JN. A reappraisal of the relationship between subepidermal immunoglobulin deposits and DNA antibodies in systemic lupus erythematosus: a study using the Crithidia luciliae immunofluorescence anti-DNA assay. J Invest Dermatol. 1979 Jan;72(1):29-32. doi:10.1111/1523-1747.ep12530158.; Carvalho MF, Coelho RA. Lupus band test: diagnostic value in disseminated lupus erythematosus. Acta Med Port. Sep-Oct 1991; 4(5):242-8.; Carroll M, Mellick N, Wagner G. Dermatomyositis panniculitis: a case report. Australas J Dermatol. 2015 Aug;56(3):224-6. doi:10.1111/ajd.12172. Epub 2014 Apr 1.; Антелава ОА, Егорова ОН, Белов БС и др. Панникулит при дерматомиозите. Научно-практическая ревматология. 2016;54(2):227-32.; Solons R, Cortes J, Selva A, et al. Panniculitis: a cutaneous manifestation of dermatomyositis. J Am Acad Dermatol. 2002 May; 46(5 Suppl):S148-50. doi:10.1067/mjd.2002.107491.; Rivas OMM, Villa VA, Lara GL, et al. Panniculitis in juvenile dermatomyositis. Clin Exp Dermatol. 2015 Jul;40(5):574-5. doi:10.1111/ced.12576. Epub 2015 Feb 16.; Salman A, Kasapcopur O, Ergun T, et al. Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work. J Dermatol. 2016;43(8):951-3.; Arias M, Hernandez MI, Cunha LG, Kien MC, Abeldaсo A. Panniculitis in a patient with dermatomyositis. An Bras Dermatol. Jan-Feb 2011;86(1):146-8. doi:10.1590/s0365-05962011000100023.; Azevedo PO, Castellen NR, Salai AF, et al. Panniculitis associated with amyopathic dermatomyositis. An Bras Dermatol. Jan-Feb 2018;93(1):119-21. doi:10.1590/abd1806-4841.20186597.; Calle A, La Fe P. Dermatomyositis panniculitis: A case series and review of the literature. JAAD 2018;104(79):3. doi:10.1016/j.jaad.2018.05.445; Bisht A, Parajuli N, Vaidya M, Tiwari S. Panniculitis as an Initial Presentation of Dermatomyositis: A Case Report. JNMA J Nepal Med Assoc. 2020 Mar;58(223):181-4. doi:10.31729/jnma.4827.; Santos-Briz A, Calle A, Linos K, et al. Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1352-9. doi:10.1111/jdv.14932. Epub 2018 Mar 27.; Pinto AS, Santos FC, Dinis SP, et al. Painful erythematoviolaceous nodules in dermatomyositis. Rheumatology (Oxford). 2021 Mar 2;60(3):1573-4. doi:10.1093/rheumatology/keaa455.; Хаитов РМ. Иммунология: структура и функции иммунной системы. Москва: ГЭОТАР-Медиа; 2019. С. 155-60.; Oon S, Monaghan K, Ng M, et al. A potential association between IL-3 and type I and III interferons in systemic lupus erythematosus. Clin Transl Immunology. 2019 Dec 24;8(12):e01097. doi:10.1002/cti2.1097.eCollection 2019.; Leonard D, Eloranta ML, Hagberg N, et al. Activated T cells enhance interferonproduction by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes. Ann Rheum Dis. 2016 Sep;75(9): 1728-34. doi:10.1136/annrheumdis-2015-208055. Epub 2015 Oct 22.; McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008 May;35(5):452-6. doi:10.1111/j.1600-0560.2007.00848.x. Epub 2007 Nov 12.; https://mrj.ima-press.net/mrj/article/view/1257

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1257
https://doi.org/10.14412/1996-7012-2022-1-84-90

المؤلفون: O. N. Egorova, G. M. Tarasova, A. V. Datsina, О. Н. Егорова, Г. М. Тарасова, А. В. Дацина

المساهمون: The investigation has been conducted within scientific research work "Innovative technologies for the diagnosis and treatment of systemic diseases of the connective tissue" (IKBRS 0397-2020-0006)., Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 16, № 3 (2022); 103-109 ; Современная ревматология; Том 16, № 3 (2022); 103-109 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: гистологические особенности, children, clinical options, diagnostics, histological features, дети, клинические варианты, диагностика

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1306/1258; Hoeger Р, Kinsler V, Yan A, et al. Harper's Textbook of Pediatric Dermatology. 4th ed. John Wiley & Sons Ltd.; 2020. P. 1207-20.; Wick MR. Panniculitis: A summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi:10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.; Caputo V, Rongioletti F. Panniculitis in the setting of dermato/rheumatologic diseases. G Ital Dermatol Venereol. 2018 Apr;153(2): 194-207. doi:10.23736/S0392-0488.17.05845-X. Epub 2017 Dec 15.; Мусатов ИД, Раденска-Лоповок СГ, Егорова ОН, Коломейчук АА. Морфологические особенности лобулярного панникулита при системной красной волчанке и дерматомиозите. Современная ревматология. 2022;16(1):84-90.; Velter C, Lipsker D. Cutaneous panniculitis. Rev Med Interne. 2016 Nov;37(11):743-50. doi:10.1016/j.revmed.2016.05.008. Epub 2016 Jun 16.; Раденска-Лоповок СГ, Егорова ОН, Белов БС и др. Идиопатический лобулярный панникулит: клинико-морфологические корреляции. Архив патологиию 2019; 81(3):37-44.; Del Pozzo Magana BR, Ho N. Subcutaneous fat necrosis of the newborn: a 20 year retrospective study. Pediatr Dermatol. 2016 Nov; 33(6):e353-e355. doi:10.1111/pde.12973. Epub 2016 Aug 30.; Lara LG, Villa AV, Rivas MM, et al. Subcutaneous fat necrosis of the newborn: report of five cases. Pediatr Neonatol. 2017 Feb;58(1): 85-8. doi:10.1016/j.pedneo.2014.06.010. Epub 2014 Nov 26.; Stefanko NS, Drolet BA. Subcutaneous fat necrosis of the newborn and associated hypercalcemia: a systematic review of the literature. Pediatr Dermatol. 2019 Jan;36(1):24-30. doi:10.1111/pde.13640. Epub 2018 Sep 6.; Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol. 2008 Jul;28(7):453-60. doi:10.1038/jp.2008.33. Epub 2008 Mar 27.; Buster KJ, Burford HN, Stewart FA, et al. Sclerema neonatorum treated with intravenous immunoglobulin: a case report and review of treatments. Cutis. 2013 Aug;92(2):83-7.; Quesada Cortes A, Campos Munoz L, Diaz Diaz RM, Casado Jimenez M. Cold panniculitis. Dermatol Clin 2008;26:485–9, vii; Ohmura K. Nakajo-Nishimura syndrome and related proteasome-associated autoinflammatory syndromes. J Inflamm Res. 2019 Sep 17;12:259-65. doi:10.2147/JIR.S194098. eCollection 2019.; Федоров ЕС, Салугина СО, Кузьмина НН. Развитие учения об аутовоспалительных заболеваниях в XXI веке. Научно-практическая ревматология 2018;56(4):5-18.; Polat A, Dinulescu M, Fraitag S, et al. Skin manifestations among GATA2-deficient patients. Br J Dermatol. 2018 Mar;178(3):781-5. doi:10.1111/bjd.15548. Epub 2017 Oct 11.; Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: A protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014 Feb 6;123(6):809-21. doi:10.1182/blood-2013-07-515528. Epub 2013 Nov 13.; Chasset F, Fayand A, Moguelet P, et al. Clinical and pathological dermatological features of deficiency of adenosine deaminase 2: A multicenter, retrospective, observational study. J Am Acad Dermatol. 2020 Dec;83(6): 1794-8. doi:10.1016/j.jaad.2020.03.110. Epub 2020 Apr 10.; Shwin KW, Lee CR, Goldbach-Mansky R. Dermatologic Manifestations of Monogenic Autoinflammatory Diseases. Dermatol Clin. 2017 Jan;35(1):21-38. doi:10.1016/j.det.2016.07.005.; Luchsinger I, Coulombe J, Rongioletti F, et al. Self-healing juvenile cutaneous mucinosis: Clinical and histopathologic findings of 9 patients: The relevance of long-term followup. J Am Acad Dermatol. 2018 Jun;78(6): 1164-70. doi:10.1016/j.jaad.2017.10.023. Epub 2017 Oct 21.; Егорова ОН, Белов БС. Панникулиты в практике дерматовенеролога и интерниста. Consilium Medicum. 2020;22(7):78-83.; Mills L, Randall MM. Disseminated coccidioidomycosis presenting as fever of unknown origin and erythema nodosum in a 3-year-old child. Case Rep Pediatr. 2021 Oct 15;2021:1755163. doi:10.1155/2021/1755163. eCollection 2021.; Jang HJ, Suh HR, Choi S, et al. Severe disease activity based on the paris classification is associated with the development of extraintestinal manifestations in korean children and adolescents with ulcerative colitis. J Korean Med Sci. 2021 Nov 15;36(44):e278. doi:10.3346/jkms.2021.36.e278.; Федоров ЕС, Каменец ЕА, РаденскаЛоповок СГ и др. Синдром Блау или саркоидоз с ранним началом. Педиатрия. 2016; 95(3):86-94.; Saghir S, Meskini T, Ettair S, et al. Weber-Christian's disease: a preleukemic disorder? Pan Afr Med J. 2019 Mar 18;32:127. doi:10.11604/pamj.2019.32.127.16106.; El Masnaoui N, Boujemaa Y, Asermouh A, et al. La maladie de Weber-Christian chez un nourrisson: а propos d'une observation. Journal de Pediatrie et de Puericulture. 2010;23:272-4.; Попов ИВ, Быстров АВ, Гамаюнов БН, Сучкова ТН. Панникулит Пфейфера Вебера Крисчена (Клиническое наблюдение). Детская больница. 2010;(1):38-40.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Идиопатический лобулярный панникулит как общеклиническая проблема. Терапевтический архив. 2019;91(5):49-53.; Noh G, Han CW. Intravenous immune globulin therapy after unsuccessful treatment with corticosteroid and cyclosporine a in Pfeifer-Weber-Christian disease: a case report. Am J Case Rep. 2021 Jan 4; 22:e929519. doi:10.12659/AJCR.929519.; Asano Y, Idezuki T, Igarashi A. A case of Rothmann-Makai panniculitis successfully treated with tetracycline. Clin Exp Dermatol. 2006 May;31(3):365-7. doi:10.1111/j.1365-2230.2005.02055.x.; Матвеева СА. Диагноз панникулита Ротмана-Макаи. Клин Мед (Моск). 1994; 72(3):52-3.; Levy J, Burnett ME, Magro CM. Lipophagic Panniculitis of Childhood: A Case Report and Comprehensive Review of the Literature. Am J Dermatopathol. 2017 Mar;39(3): 217-24. doi:10.1097/DAD.0000000000000721.; Sanmartin O, Requena C, Requena L. Factitial panniculitis. Dermatol Clin. 2008 Oct;26(4):519-27, viii. doi:10.1016/j.det.2008.05.013.; Boyd AS, Ritchie C, Likhari S. Munchausen syndrome and Munchausen syndrome by proxy in dermatology. J Am Acad Dermatol. 2014 Aug;71(2):376-81. doi:10.1016/j.jaad.2013.12.028. Epub 2014 Mar 6.; Boyd AS, Wester AC. Pancreatic fat necrosis in a 10-year-old girl: A case report and review of the literature. Pediatr Dermatol. 2019 Nov;36(6):982-3. doi:10.1111/pde.13986. Epub 2019 Aug 18.; Loverdos I, Swan MC , Shekherdimian S, et al. A case of pancreatitis, panniculitis and polyarthritis syndrome: elucidating the pathophysiologic mechanisms of a rare condition. J Pediatr Surg Case Rep. 2015 May;3(5): 223-6. doi:10.1016/j.epsc.2015.03.014.; Lichtenbeld EA, Ter Borg EJ, Venneman NG, et al. Pancreatic panniculitis with polyarthritis: PPPsyndrome. Ned Tijdschr Geneeskd. 2021 Apr 28;165:D5135.; Тorres-Duran M, Lopez-Campos JL, Barrecheguren M, et al. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions. Orphanet J Rare Dis. 2018 Jul 11; 13(1):114. doi:10.1186/s13023-018-0856-9.; Hendrick SJ, Silverman AK, Solomon AR, Headington JT. Alpha 1-antitrypsin deficiency associated with panniculitis. J Am Acad Dermatol. 1988 Apr;18(4 Pt 1):684-92. doi:10.1016/s0190-9622(88)70091-2.; Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: An update. Br J Dermatol. 2016 Apr;174(4):753-62. doi:10.1111/bjd.14309. Epub 2016 Jan 27.; Espirito Santo J, Gomes MF, Gomes MJ, et al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):307-18. doi:10.1007/s12016-009-8162-x.; Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical characteristics of lupus erythematosus panniculitis/profundus: a retrospective review of 61 patients. JAMA Dermatol. 2020 Nov 1; 156(11):1264-6. doi:10.1001/jamadermatol.2020.2797.; Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al. Neonatal lupuserythematosus – practical guidelines. J Perinat Med. 2021 Jan 18;49(5):529-38. doi:10.1515/jpm-2020-0543.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Peters MS, Su WP. Lupus erythematosus panniculitis. Med Clin North Am. 1989 Sep; 73(5):1113-26. doi:10.1016/s0025-7125(16)30622-8.; Salman A, Kasapcopur O, Ergun T, et al. Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work. J Dermatol. 2016 Aug;43(8):951-3. doi:10.1111/1346-8138.13335.; Абрамов ДС, Коновалов ДМ, Рогожин ДВ и др. Подкожная панникулит-подобная Т-клеточная лимфома у детей. Обзор литературы и описание случаев из практики. Онкогематология. 2013;(2):34-40.; Гарлоева ЮН, Фоминых ВВ, Шелихова ЛН и др. Панникулитоподобная Т-клеточная лимфома у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019;18(1):81 87.; Chaweephisal P, Sosothikul D, Polprasert C, et al. Subcutaneous Panniculitis-like T-Cell Lymphoma With Hemophagocytic Lymphohistiocytosis Syndrome in Children and Its Essential Role of HAVCR2 Gene Mutation Analysis. J Pediatr Hematol Oncol. 2021 Jan;43(1):e80-e84. doi:10.1097/MPH.0000000000001954; https://mrj.ima-press.net/mrj/article/view/1306

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1306
https://doi.org/10.14412/1996-7012-2022-3-103-109

المؤلفون: O. N. Egorova, R. G. Goloeva, D. I. Abdulganieva, О. Н. Егорова, Р. Г. Голоева, Д. И. Абдулганиева

المساهمون: Исследование выполнено в рамках научного исследования «Инновационные технологии диагностики и лечения системных заболеваний» (№0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 15, № 4 (2021); 31-37 ; Современная ревматология; Том 15, № 4 (2021); 31-37 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: поражение суставов, septal panniculitis, erythema nodosum, joint affection, септальный панникулит, узловатая эритема

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1167/1124; Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020 Aug; 16(8):465-70. doi:10.1038/s41584-020-0451-z. Epub 2020 Jun 19.; Li My, LIL, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020 Apr 28;9(1):45. doi:10.1186/s40249-020-00662-x.; Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020 Jul;183(1):71-7. doi:10.1111/bjd.19163. Epub 2020 Jun 10.; Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020 Aug 25; 324(8):782-93. doi:10.1001/jama.2020.12839.; Mendelson M, Nel J, Blumberg L, et al. Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2020 Nov 23;111 (1):10-2. doi:10.7196/SAMJ.2020.v111i11.15433.; Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute Covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026. doi:10.1136/bmj.m3026.; Chan AT, Drew DA, Nguyen LH, et al. The Coronavirus Pandemic Epidemiology (COPE) Consortium: A call to action. Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7): 1283-9. doi:10.1158/1055-9965.EPI-20-0606. Epub 2020 May 5.; Dani M, DirksenA, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e67. doi:10.7861/clinmed.2020-0896. Epub 2020 Nov 26.; Fernandez-de-las-Penas C, PalaciosCena D, Gomez-Mayordomo V, et al. Florencio, Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int J Environ Res Public Health. 2021 Mar 5; 18(5):2621. doi:10.3390/ijerph18052621.; Shah W, Hillman Т, Playford ЕD, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021 Jan 22; 372:n136. doi:10.1136/bmj.n136.; Marks M, Marks JL. Viral arthritis. Clin Med (Lond). 2016 Apr;16(2):129-34. doi:10.7861/clinmedicine.16-2-129.; Friedman N, Alter H, Hindiyeh M, et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses. 2018 Sep 21;10(10):515. doi:10.3390/v10100515.; Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet. 2020 Mar 28;395(10229):1063-77. doi:10.1016/S0140-6736(19)33221-0. Epub 2020 Mar 4.; Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18): 1708-20. doi:10.1056/NEJMoa2002032. Epub 2020 Feb 28.; Recalcati S. Cutaneous manifestations in COVID-19; a first perspective. J Eur Acad Dermatol Venereol. 2020 May;34(5):e212-e213. doi:10.1111/jdv.16387.; Manalo IF, Smith MK, Cheeley J, et al. A dermatologic manifestation of COVID-19: transient Livedo reticularis. J Am Acad Dermatol. 2020 Aug;83(2):700. doi:10.1016/j.jaad.2020.04.018. Epub 2020 Apr 10.; Gottlieb М, Long В. Dermatologic manifestations and complications of COVID-19. Am J Emerg Med. 2020 Sep;38(9):1715-21. doi:10.1016/j.ajem.2020.06.011. Epub 2020 Jun 6.; Егорова ОН, Белов БС. Панникулиты в практике дерматовенеролога и интерниста. Consilium Medicum. 2020;22(7):78-83.; Rebsamen U, Guenova Е, Vallelian F. CME: Erythema nodosum. Praxis (Bern 1994). 2017 Sep;106(18):973-9. doi:10.1024/1661-8157/a002775.; Golisch KB, Gottesman SP, Segal RJ. Compression stockings as an effective treatment for erythema nodosum: Case series. Int J Womens Dermatol. 2017 Sep 29;3(4):231-3. doi:10.1016/j.ijwd.2017.09.001. eCollection 2017 Dec.; Suter Р, Mooser В, Pham Huu Thien HP. Erythema nodosum as a cutaneous manifestation of COVID-19 infection. BMJ Case Rep. 2020 Jul 8;13(7):e236613. doi:10.1136/bcr-2020-236613.; Ordieres-Ortega L, Toledo-Samaniego N, Parra-Virto A, et al. Atypical erythema nodosum in a patient with COVID-19 pneumonia. Dermatol Ther. 2020 Jul;33(4):e13658. doi:10.1111/dth.13658. Epub 2020 Jun 15.; Sipfle N, Bridwell RE, Roper J. Erythema nodosum-like rash in a COVID-19 patient: A case report. Am J Emerg Med. 2021 Feb;40: 227.e1-227.e2. doi:10.1016/j.ajem.2020.07.063. Epub 2020 Jul 30.; Nath A. Long-Haul COVID. Neurology. 2020 Sep 29;95(13):559-60. doi:10.1212/WNL.0000000000010640. Epub 2020 Aug 11.; Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-32. doi:10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.; Lara B, Carnes A, F Dakterzada F, et al. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown. Eur J Neurol. 2020 Sep;27(9):1744-7. doi:10.1111/ene.14339. Epub 2020 Jun 24.; Yokogawa N, Minematsu N, Katano H, Suzuki T. Case of acute arthritis following SARS-CoV-2 infection. Ann Rheum Dis. 2020 Jun 26;annrheumdis-2020-218281. doi:10.1136/annrheumdis-2020-218281. Online ahead of print.; Saricaoglu EM, Hasanoglu I, Guner R. The first reactive arthritis case associated with COVID-19. J Med Virol. 2021 Jan;93(1): 192-3. doi:10.1002/jmv.26296. Epub 2020 Jul 19.; De Stefano L, Rossi S, Montecucco C, Bugatti S. Transient monoarthritis and psoriatic skin lesions following COVID-19. Ann Rheum Dis. 2020 Aug 4;annrheumdis-2020-218520. doi:10.1136/annrheumdis-2020-218520. Online ahead of print.; Liew IY, Mak TM, Cui L, et al. A case of reactive arthritis secondary to coronavirus disease 2019 infection. J Clin Rheumatol. 2020 Oct;26(7):295-300. doi:10.1097/RHU.0000000000001116.; Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020 Aug;6(2):e001350. doi:10.1136/rmdopen-2020-001350.; Kamal M, Omirah MA, Hussein A, Haitham Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021 Mar;75(3):e13746. doi:10.1111/ijcp.13746. Epub 2020 Nov 3.; Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi:10.1093/cid/ciaa248.; McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020 Jun;19(6):102537. doi:10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.; Prompetchara E, Ketloy С, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. doi:10.12932/AP200220-0772.; Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4. doi:10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.; Amoli MM, Miranda-Filloy JA, Vazquez-Rodriguez TR, et al. Interleukin-1 Beta Gene Polymorphism in Patients With BiopsyProven Erythema Nodosum. Clin Exp Rheumatol. Jan-Feb 2011;29(1 Suppl 64): S131-2. Epub 2011 May 11.; Amoli MM, Miranda-Filloy JA, Fernandez-Diaz ML, et al. Interleukin-6 Promoter Polymorphism at Position -174 in Biopsy-Proven Patients With Erythema Nodosum From a Defined Population. Clin Exp Rheumatol. May-Jun 2008;26(3 Suppl 49):S155-6.; De Simone C, Caldarola G, Scaldaferri F, et al. Clinical, Histopathological, and Immunological Evaluation of a Series of Patients with Erythema Nodosum. Int J Dermatol. 2016 May;55(5):e289-94. doi:10.1111/ijd.13212. Epub 2016 Feb 24.; Wendling D, Verhoeven F, Chouk M, Prati C. Can SARS-CoV-2 trigger reactive arthritis? Joint Bone Spine. 2021 Jan;88(1): 105086. doi:10.1016/j.jbspin.2020.105086. Epub 2020 Oct 27.; Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020 Jun;20(6):345-6. doi:10.1038/s41577-020-0328-z.; https://mrj.ima-press.net/mrj/article/view/1167

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1167
https://doi.org/10.14412/1996-7012-2021-4-31-37

المؤلفون: O. N. Egorova, B. S. Belov, E. G. Sazhina, О. Н. Егорова, Б. С. Белов, Е. Г. Сажина

المصدر: Modern Rheumatology Journal; Том 15, № 3 (2021); 75-80 ; Современная ревматология; Том 15, № 3 (2021); 75-80 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: шкала оценки коморбидности CIRS, lipodermatosclerosis, comorbidity, Charlson index, scale for assessing comorbidity CIRS, липодерматосклероз, коморбидность, индекс Charlson

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1152/1113; https://mrj.ima-press.net/mrj/article/view/1152/1114; Campbell-Scherer D. Multimorbidity challenge ofevidence-based medicine. Evid Based Med. 2010 Dec;15(6):165-6. doi:10.1136/ebm1154.; Насонов ЕЛ, Гордеев АВ, Галушко ЕА. Ревматические заболевания и многоморбидность. Терапевтический архив. 2015;87(5):4-9.; Вербовая АФ, Цанава ИА, Вербовая НИ. Медицина XXI века: в фокусе коморбидность.Университетская медицина Урала. 2017;(2):27-31.; Litwin MS, Greenfield S, Elkin EP. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777-83. doi:10.1002/cncr.22615.; Von Korff MA, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992 Feb; 45(2):197-203. doi:10.1016/0895-4356(92)90016-g.; Starfield B, Weiner J, Mumford L. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res. 1991 Apr;26(1):53-74.; Rozzini R, Frisoni GB, Barbisoni P, et al. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbid¬ity. Age Ageing. 2002 Jul;31(4): 277-85. doi:10.1093/ageing/31.4.277.; Kaplan MH, Feinstein AR. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus. Diabetes. 1973 Mar;22(3):160-74. doi:10.2337/diab.22.3.160.; Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol. 1993 Apr;46(4): 379-93. doi:10.1016/0895-4356(93)90153-r.; Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8.; Сарсенбаева ГИ, Турсынбекова АЕ. Современные подходы к оценке коморбидности у пациентов. CardioСоматика. 2019;(1):19-23.; Miller MD, Towers A. Manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg: University of Pittsburgh; 1991. 31 p.; Greenfield S, Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: comorbidity and outcomes after hipreplacement. Med Care. 1993 Feb;31(2): 141-54. doi:10.1097/00005650-199302000-00005.; Grolla DL, Tob T, Bombardiere C. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005 Jun;58(6):595-602. doi:10.1016/j.jclinepi.2004.10.018.; De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003 Mar;56(3):221-9. doi:10.1016/s0895-4356(02)00585-1.; Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr. 2016 Nov; 128(21-22):786-90. doi:10.1007/s00508-016-1090-x. Epub 2016 Oct 13.; Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi:10.1186/ar2669. Epub 2009 May 19.; Панафидина ТА, Кондратьева ЛВ, Герасимова ЕВ и др. Коморбидность при ревматоидном артрите. Научно-практическая ревматология. 2014;52(3):283-9.; Клюквина НГ. Проблема коморбидности при системной красной волчанке. Русский медицинский журнал. 2015;(7): 370-4.; Балабанова РМ. Анкилозирующий спондилит и коморбидность: безопасность длительного применения нимесулида. Современная ревматология. 2017;11(4): 79-82.; Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi:10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.; Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. Jul-Aug 2010;23(4):375-88. doi:10.1111/j.1529-8019.2010.01338.x.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Липодерматосклероз как разновидность лобулярного панникулита: клинические особенности. Клиницист. 2015;(9):28-34.; Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec;40(6):1248-52. doi:10.1016/j.jvs.2004.09.027.; Савельев ВС, Гологорский ВА, Кириенко АИ и др. Флебология. Руководство для врачей. Москва: Медицина; 2001.; Ocampo VD, Gladman M. Psoriatic arthritis Version 1. F1000Res. 2019 Sep 20; 8:F1000 Faculty Rev-1665. doi:10.12688/f1000research.19144.1. eCollection 2019.; Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. doi:10.7326/0003-4819-120-2-199401150-00002.; Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. https://seer.cancer.gov/archive/csr/1975_2007/; Никитина НМ, Афанасьев ИА, Ребров АП. Коморбидность у больных ревматоидным артритом. Научно-практическая ревматология. 2015;53(2):149-54.; Nikitina NM, Afanas'ev IA, Rebrov AP. Comorbidity in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(2):149-54. (In Russ.).; Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumaticdiseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi:10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16.; Frewen J, Hughes AJ, Denny J, Natkunarajah J. Lipodermatosclerosis of the pendulous abdomen. Clin Exp Dermatol. 2020 Jul;45(5):626-7. doi:10.1111/ced.14210. Epub 2020 Apr 22.; Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study. Comparative Study Am J Epidemiol. 1997 Mar 1;145(5):408-15. doi:10.1093/oxfordjournals.aje.a009122.; Essers I, Stolwijk С, Boonen А, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Multicenter study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi:10.1136/annrheumdis-2014-206147. Epub 2014 Oct 31.; https://mrj.ima-press.net/mrj/article/view/1152

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1152
https://doi.org/10.14412/1996-7012-2021-3-75-80

المؤلفون: A. S. Potapova, O. N. Egorova, O. G. Alekseeva, A. V. Volkov, D. M. Kudinsky, А. С. Потапова, О. Н. Егорова, О. Г. Алексеева, А. В. Волков, Д. М. Кудинский

المصدر: Modern Rheumatology Journal; Том 15, № 2 (2021); 77-82 ; Современная ревматология; Том 15, № 2 (2021); 77-82 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: лечение, antiphospholipid syndrome, diagnostics, treatment, склеродерма-панникулит, антифосфолипидный синдром, диагностика

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1126/1085; https://mrj.ima-press.net/mrj/article/view/1126/1096; Егорова ОН, Белов БС. Панникулиты в практике дерматовенеролога и интерниста. Consilium Medicum. 2020;22(7):78-83.; Wick MR. Panniculitis: а summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi:10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.; Caputo V, Rongioletti F. Panniculitis in the setting of dermato/rheumatologic diseases. G Ital Dermatol Venereol. 2018 Apr;153(2): 194-207. doi:10.23736/S0392-0488.17.05845-X. Epub 2017 Dec 15.; Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001 Aug;45(2):163-83; quiz 184-6. doi:10.1067/mjd.2001.114736.; Requena L, Yus ES. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4. doi:10.1067/mjd.2001.114735.; Раденска-Лоповок СГ, Егорова ОН, Белов БС и др. Идиопатический лобулярный панникулит: клинико-морфологические корреляции. Архив патологии. 2019;81(3):37-44.; Bö er-Auer A. Differenzialdiagnostik der Pannikulitis. Hautarzt. 2016 Jul;67(7):555-69. doi:10.1007/s00105-016-3794-2.; Peterson LS, Nelson AM, Su WP, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-93. J Rheumatol. 1997 Jan;24(1):73-80.; Lafyatis R., Farina V. New understanding of the mechanisms of innate immunity receptor signaling in fibrosis. Open Rheumatol J. 2012;6:72-9. doi:10.2174/1874312901206010072. Epub 2012 Jun 15.; Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford). 2009 Mar;48(3): 213-21. doi:10.1093/rheumatology/ken405. Epub 2008 Nov 20.; Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005 Sep; 52(9):2873-81. doi:10.1002/art.21264.; Романова НВ. Иммунопатологические нарушения и цитокиновый профиль при системной и ограниченной склеродермии.Терапевтический архив. 2012;(5):28-31.; Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018 Aug; 65(4):757-81. doi:10.1016/j.pcl.2018.04.002.; Scalapino K, Arkaschaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006 May;33(5): 1004-13. Epub 2006 Apr 1.; George R, George A, Kumar TS. Update on management of Morphea (Localized Scleroderma) in childrenIndian. Indian Dermatol Online J. 2020 Mar 9;11(2):135-45. doi:10.4103/idoj.IDOJ_284_19. eCollection Mar-Apr 2020.; Careta MF, Romiti R. Localized scleroderma: Clinical spectrum and therapeutic update. An Bras Dermatol. Jan-Feb 2015; 90(1):62-73. doi:10.1590/abd1806-4841.20152890.; Lis-Swiety А, Brzezinska-Wcislo L, Arasiewicz Н, Bergler-Czop В. Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome. Postepy Dermatol Alergol. 2014 May; 31(2):65-70. doi:10.5114/pdia.2014.40978. Epub 2014 Apr; 18. Hunt RD, Robinson М, Patel R, Franks AG. Antiphospholipid-antibody-associated panniculitis. Dermatol Online J. 2012 Dec 15;18(12):18.; Renfro L, Franks AG, Grodberg M, Kamino H. Painful nodules in a young female: antiphospholipid syndrome. Arch Dermatol. 1992 Jun;128(6):847-8, 850-1. doi:10.1001/archderm.1992.01680160133022.; Jimenez-Mazuecos J, Yebra-Bango M, Sanchez-Ruiz A, Villarreal-Garcia-Lomas M. Weber-Christian disease associated with lupus anticoagulant and anticardiolipin antibodies. Rheumatology (Oxford). 1999 Aug; 38(8):796-7. doi:10.1093/rheumatology/38.8.796.; Torok КS, Li SС, Jacobe НМ, et al. Immunopathogenesis of Pediatric Localized Scleroderma. Front Immunol. 2019 Apr 30; 10:908. doi:10.3389/fimmu.2019.00908. eCollection 2019.; Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011 Dec;165(6):1308-13. doi:10.1111/j.1365-2133.2011.10600.x. Epub 2011 Nov 2.; Wu EY, Li SC, Torok KS, et al. Baseline description of the juvenile localized scleroderma subgroup from the childhood arthritis and rheumatology research alliance legacy registry. ACR Open Rheumatol. 2019 Apr 10; 1(2):119-24. doi:10.1002/acr2.1019. eCollection 2019 Apr.; Li SC, Li X, Pope E, et al. New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. J Rheumatol. 2018 Dec;45(12):1680-8. doi:10.3899/jrheum.171381. Epub 2018 Sep; 25. Schoch J, Schoch B, Davis D. Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Pediatr Dermatol. 2018 Jan;35(1):43-6. doi:10.1111/pde.13336. Epub 2017 Nov 9.; Kimball H, Kimball D, Siroy A, et al. Novel diagnostic imaging features of facial lupus panniculitis: ultrasound, CT, and MR imaging with histopathology correlate. Clin Imaging. Nov-Dec 2019;58:177-81. doi:10.1016/j.clinimag.2019.07.006. Epub 2019 Jul 23.; Hemmi S, Kushida R, Nishimura H, et al. Magnetic resonance imaging diagnosis of panniculitis in dermatomyositis. Muscle Nerve. 2010 Jan;41(1):151-3. doi:10.1002/mus.21537.; Romani J, Giavedoni P, Roe E, et al. Inter- and Intra-rater Agreement of Dermatologic Ultrasound for the Diagnosis of Lobular and Septal Panniculitis. J Ultrasound Med. 2020 Jan;39(1):107-12. doi:10.1002/jum.15080. Epub 2019 Jun 27.; Cid PM, Flores CR, Caelles IP, et al. High-frequency ultrasound features in a case of gouty panniculitis. Dermatol Online J. 2017 Jun 15;23(6):13030/qt33j2z14m.; Егорова ОН, Белов БС. Панникулиты: ревматологические аспекты. Современная ревматология. 2018;12(2):73-8. doi: 10/14412/1996-7012-2018-2-73-78.; Narbutt J, Holdrowicz A, Lesiak A. Morphea – Selected local treatment methods and their effectiveness. Reumatologia. 2017; 55(6):305-13. doi:10.5114/reum.2017.72628. Epub 2017 Dec 30.; Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriolbetamethasone dipropionate for morphoea. Br J Dermatol. 2007 Sep;157(3):615-8. doi:10.1111/j.1365-2133.2007.07971.x. Epub 2007 Jun 6.; Koch SB, Cerci FB, Jorizzo JL, Krowchuk DP. Linear morphea: A case series with long-term follow-up of young, methotrexate-treated patients. J Dermatolog Treat. 2013 Dec;24(6):435-8. doi:10.3109/09546634.2013.806769. Epub 2013 Jul 15.; Martini G, Ramanan AV, Falcini F, et al. Successful treatment of severe or methotrexateresistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford). 2009 Nov;48(11):1410-3. doi:10.1093/rheumatology/kep244. Epub 2009 Aug 27.; Kumar AB, Blixt EK, Drage LA, et al. Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. J Am Acad Dermatol. 2019 Jun;80(6):1658-63. doi:10.1016/j.jaad.2019.01.040. Epub 2019 Jan 29.; Bali G1, Frü hauf J, Wutte N, Aberer E. Cyclosporine reduces sclerosis in morphea: A retrospective study in 12 patients and a literature review. Dermatology. 2016;232(4): 503-10. doi:10.1159/000448171. Epub 2016 Aug 30.; Zhang A, Nocton J, Chiu Y. A case of pansclerotic morphea treated with tocilizumab. JAMA Dermatol. 2019 Mar 1;155(3): 388-9. doi:10.1001/jamadermatol.2018.5040.; Kim SR, Charos A, Damsky W, et al. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018 Apr 30;4(5):443-5. doi:10.1016/j.jdcr.2017.12.003. eCollection 2018 Jun.; https://mrj.ima-press.net/mrj/article/view/1126

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1126
https://doi.org/10.14412/1996-7012-2021-2-77-82

المؤلفون: Z. S. Alekberova, O. N. Egorova, R. G. Goloeva, M. V. Cherkasova, З. С. Алекберова, О. Н. Егорова, Р. Г. Голоева, М. В. Черкасова

المصدر: Modern Rheumatology Journal; Том 15, № 1 (2021); 105-110 ; Современная ревматология; Том 15, № 1 (2021); 105-110 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: иммунодепрессанты, systemic lupus erythematosus, glucocorticoids, immunosuppressants, системная красная волчанка, глюкокортикоиды

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1108/1066; Gasparin AA, Chakr RM, Brenol CV, et al. Anti-Mü llerian hormone levels as a predictor of ovarian reserve in systemic lupus erythematosus patients: a review. Rev Bras Reumatol. 2015 Jul-Aug;55(4):363-7. doi:10.1016/j.rbr.2014.05.008. Epub 2014 Nov 26.; Lee MM, Donahoe PK. Mü llerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev. 1993 Apr;14(2): 152-64. doi:10.1210/edrv-14-2-152.; La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mü llerian hormone throughout the human menstrual cycle. Hum Reprod. 2006 Dec;21(12):3103-7. doi:10.1093/humrep/del291. Epub 2006 Aug 21.; Visser JA, De Jong FH, Laven JS, Themmen AP. Anti-Mü llerian hormone: a new marker for ovarian function. Reproduction. 2006 Jan;131(1):1-9. doi:10.1530/rep.1.00529.; Freour T, Mirallie S, Bach-Ngohou K, et al. Measurement of serum anti-Mü llerian hormone by Beckman Coulter Elisa and DSL Elisa: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007 Jan;375(1-2):162-4. doi:10.1016/j.cca.2006.06.013. Epub 2006 Jun 20.; Broekmans FJ, Kwee J, Hendriks DJ. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006 Nov-Dec;12(6):685-718. doi:10.1093/humupd/dml034. Epub 2006 Aug 4.; Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mü llerian hormone measurement in a routine IVF program. Hum Reprod. 2008 Jun;23(6):1359-65. doi:10.1093/humrep/den108. Epub 2008 Apr 2.; Jayaprakasan K, Pandian D, Hopkisson J, et al. Effect of ethnicity on live birth rates after in vitro fertilisation or intracytoplasmic sperm injection treatment. BJOG. 2014 Feb; 121(3):300-6. doi:10.1111/1471-0528.12504. Epub 2013 Nov 6.; Bleil ME, Gregorich SE, Adler NE, et al. Race/ethnic disparities in reproductive age: An examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women. Fertil Steril. 2014 Jan; 101(1):199-207. doi:10.1016/j.fertnstert.2013.09.015. Epub 2013 Oct 29.; Григорян ОР, Красновская НС, Михеев РК и др. Овариальный резерв и аутоиммунные заболевания щитовидной железы (обзор литературы). Ожирение и метаболизм. 2019;16(2):16-21.; Luo W, Mao P, Zhang L, et al. Assessment of ovarian reserve by serum antiMü llerian hormone in patients with systemic lupus erythematosus: a meta-analysis. Ann Palliat Med. 2020 Mar;9(2):207-15. doi:10.21037/apm.2020.02.11. Epub 2020 Mar 3.; Gao H, Ma J, Wang X, et al. Preliminary study on the changes of ovarian reserve, menstruation, and lymphocyte subpopulation in systemic lupus erythematosus (SLE) patients of childbearing age. Lupus. 2018 Mar;27(3): 445-53. doi:10.1177/0961203317726378. Epub 2017 Aug 18.; Malheiro OB, Rezende CP, Rocha AL, et al. Regular menstrual cycles do not rule out ovarian damage in adult women with systemic lupus erythematosus. Gynecol Endocrinol. 2014 Oct;30(10):701-4. doi:10.3109/09513590.2014.922949. Epub 2014 Jun 5.; De Araujo DB, Yamakami LY, Aikawa NE, et al. Ovarian reserve in adult patients with childhood-onset lupus: a possible deleterious effect of methotrexate? Scand J Rheumatol. 2014;43(6):503-11. doi:10.3109/03009742.2014.908237. Epub 2014 Jun 2.; Li Y, Zhao Y, Ci CZ, et al. AntiMü llerian hormone: its significance in female lupus patients and relation with anti-ovarian antibody. Chinese Journal of Rheumatology. 2010;14:305-7.; Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Mü llerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013 Sep; 98(9):3785-92. doi:10.1210/jc.2013-1235. Epub 2013 Jul 5.; Mok CC, Chan PT, To CH. Anti-Mü llerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013 Jan;65(1):206-10. doi:10.1002/art.37719.; Clara Di Mario, Luca Petricca, Maria Rita Gigante Anti-Mü llerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine. 2019 Feb;63(2):369-375. doi:10.1007/s12020-018-1783-1. Epub 2018 Oct 15.; Van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mü llerian hormone and antral follicle counts. Hum Reprod. 2010 Jan; 25(1):221-7. doi:10.1093/humrep/dep366. Epub 2009 Oct 19.; Li C, Xie J, Wang X, et al. Strong reduction of anti-Mü llerian hormone in systemic lupus erythematosus woman of reproductive age. Ann Rheum Dis. 2017;76:1226-7.; Sterba Y, Tanner T, Wahezi D. Evaluation of ovarian reserve and function in adolescent females with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:3233-4.; Ekblom-Kullberg S, Kauniainen H, Alfa P. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol. 2009;38(5):375-80. doi:10.1080/03009740902763099.; Nelson LM. Clinical practice, primary ovarian insufёciency. N Engl J Med. 2009 Feb 5;360(6):606-14. doi:10.1056/NEJMcp0808697.; Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev. 1997 Feb;18(1): 107-34. doi:10.1210/edrv.18.1.0291.; Rajpert-De Meyts E, Jorgensen N, Graem N, et al. Expression of anti-Mü llerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999 Oct;84(10): 3836-44. doi:10.1210/jcem.84.10.6047.; Bhide P, Pundir J, Homburg R, et al. Biomarkers of ovarian reserve in childhood and adolescence: a systematic review. Acta Obstet Gynecol Scand. 2019 May;98(5): 563-72. doi:10.1111/aogs.13574. Epub 2019 Mar 5.; Fanchin R, Taieb J, Lozano DH, et al. High reproducibility of serum anti-Mü llerian hormone measurements suggests a multistaged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod. 2005 Apr;20(4):923-7. doi:10.1093/humrep/deh688. Epub 2005 Jan 7.; Tsepelidis S, Devreker F, Demeestere I, et al. Stable serum levels of anti-Mü llerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007 Jul;22(7):1837-40. doi:10.1093/humrep/dem101. Epub 2007 May 7.; Somunkiran A, Yavuz T, Yucel O, et al. Anti-Mü llerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):196-201. doi:10.1016/j.ejogrb.2007.01.012. Epub 2007 Mar 1.; Shabanova SS, Ananieva LP, Alekberova ZS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. May-Jun 2008;26(3): 436-41.; Angley М, Spencer JB, Lim SS, Howards PP. Anti-Mü llerian hormone in African-American women with systemic lupus erythematosus. Lupus Sci Med. 2020 Nov;7(1):e000439. doi:10.1136/lupus-2020-000439.; Chakravarty EF, Clowse ME, Costenbader K, et al. Patient risk perception of teratogenicity of disease modifying antirheumatic drugs. Arthritis Rheum.2010;62 Suppl:S135.; Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010 Nov;5(11):2060-8. doi:10.2215/CJN.00240110. Epub 2010 Aug 5.; Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erithematosus. Rheumatology (Oxford). 2011 Sep;50(9):1551-8. doi:10.1093/rheumatology/ker105. Epub 2011 Jun 7.; Boivin J, Bunting L, Collins JA, et al. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007 Jun;22(6):1506-12. doi:10.1093/humrep/dem046. Epub 2007 Mar 21.; Costa M, Colia D. Treating infertility in autoimmune patients. Rheumatology (Oxford). 2008 Jun;47 Suppl 3:iii38-41. doi:10.1093/rheumatology/ken156.; Galey-Fontaine J, Cedrin-Durnerin I, Chaibi R, et al. Age and ovarian reserve are distinct predictive factors of cycle outcome in low responders. Reprod Biomed Online. 2005 Jan; 10(1):94-9. doi:10.1016/s1472-6483(10)60808-5.; Streuli I, Fraisse T, Pillet C, et al. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008 Aug;90(2):395-400. doi:10.1016/j.fertnstert.2007.06.023. Epub 2007 Oct 24.; Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology (Oxford). 2007 Nov;46(11):1634-40. doi:10.1093/rheumatology/kem156. Epub 2007 Jul 10.; https://mrj.ima-press.net/mrj/article/view/1108

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1108
https://doi.org/10.14412/1996-7012-2021-1-105-110

المؤلفون: O. N. Egorova, B. S. Belov, E. G. Sazhina, О. Н. Егорова, Б. С. Белов, Е. Г. Сажина

المساهمون: The investigation has been conducted within scientific topic №0397-2020-0006 «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases»., Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 15, № 5 (2021); 108-113 ; Современная ревматология; Том 15, № 5 (2021); 108-113 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: ревматические заболевания, botulinum toxin type A, rheumatic diseases, ботулинический токсин типа А

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1208/1162; Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi:10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.; Екушева ЕВ. Коморбидный пациент с хроническим болевым синдромом. Русский медицинский журнал. 2019;(9):44-8.; http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf; Насонова ВА, Каратеев АЕ. Симптоматическая терапия боли при ревматических заболеваниях: место ацеклофенака. Современная ревматология. 2009;3(3):58-65.; Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi:10.1177/0300060519895868.; Костенко ЕВ, Коновалова ЗН, Орлова ОР, Хатькова СЕ. Ботулотоксин при болевых синдромах. Медицинский совет. 2018;(1):58-63.; Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi:10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.; Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi:10.1002/ana.410330109.; Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi:10.1016/S0304-3959(01)00292-5; Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi:10.1517/14656566.2.10.1649.; Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi:10.1046/j.1526-4610.43.7s.3.x.; Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi:10.1016/j.pain.2006.04.014. Epub 2006 May 4.; Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi:10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.; Артемьев ДВ, Орлова ОР, Моренкова АЭ. Использование ботокса в медицинской практике. Неврологический журнал.2000;5(4):46-51.; Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi:10.1128/IAI.00536-13. Epub 2013 Aug 5.; Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi:10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.; Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi:10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.; Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi:10.1007/BF03033937.; Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi:10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.; Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi:10.1097/RHU.0b013e3181953b14.; Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi:10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.; Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi:10.1016/j.pain.2006.04.009. Epub 2006 May 22.; Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi:10.1038/nrdp.2016.72.; Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi:10.3389/fneur.2017.00458. eCollection 2017.; Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi:10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.; Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi:10.1111/j.1749-6632.2002.tb04234.x.; Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi:10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.; Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi:10.1016/S1726-4901(10)70126-X.; Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi:10.2147/JPR.S159700.eCollection 2018.; Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi:10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.; Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi:10.1186/1757-1146-7-9.; Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi:10.3899/jrheum.100336.Epub 2010 Sep 1.; Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi:10.1080/03009742.2016.1203988. Epub 2016 Oct 13.; McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi:10.1016/j.joca.2018.05.001. Epub 2018 May 9.; Плотникова ЕВ, Елькин ВД, Миронов АН и др. Экпериментальное обоснование к использованию в косметической практике нового отечественного иммунобиологического препарата с миорелаксатным действием «релатокс». Биология и экпериментальная медицина. 2011; XXVIII(4):125-30.; Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi:10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.; Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi:10.1111/j.1365-2362.2004.01324.x.; Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.; Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi:10.1001/archdermatol.2011.1144.; Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi:10.1097/01.prs.0000244860.00674.57.; Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi:10.1016/j.jhsa.2010.09.019.; Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi:10.1002/art.40123. Epub 2017 Jun 26.; Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi:10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.; Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi:10.1111/1346-8138.13030. Epub 2015 Jul 15.; Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi:10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.; Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi:10.1038/nrrheum.2012.96. Epub 2012 Jul 10.; Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi:10.1056/NEJMcp013013.; Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi:10.1016/j.pain.2003.10.008.; Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi:10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.; Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi:10.1097/00002508-200211001-00002.; O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi:10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.; Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi:10.1177/0194599811398596.; Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.; Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.; https://mrj.ima-press.net/mrj/article/view/1208

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1208
https://doi.org/10.14412/1996-7012-2021-5-108-113

المؤلفون: O. N. Egorova, B. S. Belov, S. G. Radenska-Lopovok, О. Н. Егорова, Б. С. Белов, С. Г. Раденска-Лоповок

المصدر: Modern Rheumatology Journal; Том 14, № 1 (2020); 57-61 ; Современная ревматология; Том 14, № 1 (2020); 57-61 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

مصطلحات موضوعية: клиническая картина, rheumatic diseases, diagnosis, clinical picture, ревматические заболевания, диагностика

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/993/952; Ter Poorten MC, Thiers BH. Panniculitis. Dermatol Clin. 2002;20(3):421-33. doi:10.1016/S0733-8635(02)00008-6; Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol. 2001;45:163-83. doi:10.1067/mjd.2001.114736; Requena L, Sanchez YuE. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-61. doi:10.1067/mjd.2001.114735; Wick MR. Panniculitis: а summary. Semin Diagn Pathol. 2017;34(3):261-72. doi:10.1053/j.semdp.2016.12.004; Вербенко ЕВ. Спонтанный панникулит. В кн.: Скрипкин ЮК, редактор. Кожные и венерические болезни. Руководство для врачей. Москва: Медицина; 1995. Т. 2. С. 399-410.; Morita TCAB, Tres GFS, Garcia MSC, et al. Panniculitides of particular interest to the rheumatologist. Adv Rheumatol. 2019 Aug 1; 59(1):35. doi:10.1186/s42358-019-0077-5; Егорова ОН, Белов БC, Глухова СИ, Раденска-Лоповок СГ. Идиопатический лобулярный панникулит как общеклиническая проблема. Терапевтический архив. 2019;91(5):49-53.; Раденска-Лоповок СГ, Егорова ОН, Белов БС и др. Особенности идиопатического панникулита – клинико-морфологические корреляции. Архив патологии. 2019;81(3):37-44.; Егорова ОН, Белов БС, Раденска-Лоповок СГ и др. К проблеме дифференциальной диагностики панникулитов. Врач. 2014;(11):14-9.; Муразян РИ, Панченков НР. Экстренная помощь при ожогах. Москва: Медицина; 1983. С. 63-4.; Антелава ОА, Насонов ЕЛ. Современные методы оценки активности и повреждения при идиопатических воспалительных миопатиях. Научно-практическая ревматология. 2007;45(1):59-62.; Kisacik B, Onat AM, Pehlivan Y. Multiclinical experiences in erythema nodosum: rheumatology clinics versus dermatology and infection diseases clinics. Rheumatol Int. 2013;33(2):315-8. doi:10.1007/s00296-012-2413-5; Kimball H, Kimball D, Siroy A, et al. Novel diagnostic imaging features of facial lupus panniculitis: ultrasound, CT, and MR imaging with histopathology correlate. Clin Imaging. 2019 Jul;58:177-81. doi:10.1016/j.clinimag.2019.07.006; Hansen CB, Callen JP. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther. 2010;23(4):341-49. doi:10.1111/j.1529-8019.2010.01334.x; Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5):536-48. doi:10.14412/1995-4484-2017-536-548.; Mangold AR, Costello CM, Cumsky HJL, et al. Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. JAAD Case Rep. 2018 Sep;4(8):789-93. doi:10.1016/ j.jdcr.2018.03.022; Kuhn A. Characterizing clinicopathological and immunohistochemical findings in dermatomyositis panniculitis. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1231-32. doi:10.1111/jdv.15149; https://mrj.ima-press.net/mrj/article/view/993

الاتاحة: https://mrj.ima-press.net/mrj/article/view/993
https://doi.org/10.14412/1996-7012-2020-1-57-61

المؤلفون: O. N. Egorova, B. S. Belov, K. G. Romanova, О. Н. Егорова, Б. С. Белов, К. Г. Романова

المساهمون: The investigation was conducted as part of the research «Comorbid infections in rheumatic diseases and the safety problems of antirheumatic therapy» (AAAA-A19-119021190148-3, 0514-2019-0005) and the applied research «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases» (0597-2020-0006)., Работа выполнена в рамках научной исследовательской работы «Коморбидные инфекции при ревматических заболеваниях и проблемы безопасности антиревматической терапии» (АААА-А19-119021190148-3, 0514-2019-0005) и прикладного научного исследования «Инновационные технологии диагностики и лечения системных заболеваний соединительных тканей» (0597-2020-0006).

المصدر: Modern Rheumatology Journal; Том 14, № 2 (2020); 35-40 ; Современная ревматология; Том 14, № 2 (2020); 35-40 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-2

مصطلحات موضوعية: синдром Лефгрена, erythema nodosum, sarcoidosis, Löfgren's syndrome, узловатая эритема, саркоидоз

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1013/974; Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69(11):1751-63. doi:10.1002/acr.23177.; Vieira MC, Tosta PG, Nicole FM, et al. Chronic inflammatory arthropathy preceding acute systemic manifestations of sarcoidosis: a possible overlap of idiopathic juvenile arthritis and sarcoidosis. Case Rep Rheumatol. 2019 Dec 7;2019:6483245. doi:10.1155/2019/6483245. eCollection 2019.; Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Саркоидоз (Федеральные согласительные клинические рекомендации). Москва; 2019. С. 6-19.; Визель ИЮ, Визель АА. Характеристика регистра больных саркоидозом в Республике Татарстан. Вестник современной клинической медицины. 2015;8(5):18-26.; Thomeer M, Demedts M, Vandeurzen K, et al. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001 May-Jun; 56(3):163-72.; Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008 Feb;31(2):372-9. Epub 2007 Oct 24.; Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011 Mar 1;183(5): 573-81. doi:10.1164/rccm.201006-0865CI. Epub 2010 Oct 29.; Kobak S, Semiz H, Akyildiz M, et al. Serum adipokine levels in patients with sarcoidosis. Clin Rheumatol. 2020. doi:10.1007/s10067-020-04980-1; Визель АА, Визель ИЮ. Саркоидоз: что мы знаем и что мы можем. Практическая пульмонология. 2018;(1):65-8.; Kobak S. Sarcoidosis: a rheumatologist's perspective. Ther Adv Musculoskelet Dis. 2015 Oct;7(5):196-205. doi:10.1177/1759720X15591310; Visser H, Vos K, Zanelli E, et al. Sarcoid arthritis: clinical characteristics,diagnostic aspects, and risk factors. Ann Rheum Dis. 2002 Jun;61(6):499-504.; Русаков НВ, Мухин НА, Брико НИ и др. Особенности распространения саркоидоза в условиях Москвы. Гигиена и санитария. 2012;(4):16-8.; Rubio-Rivas M, Franco J, Corbella X. Sarcoidosis presenting with and without Löfgren's syndrome: Clinical, radiological and behavioral differences observed in a group of 691patients. Joint Bone Spine. 2019 Oct 11. pii: S1297-319X(19)30147-2. doi:10.1016/j.jbspin.2019.10.001; Kirresh O, Schofield J, George G. Acute sarcoidosis: Löfgren's syndrome. Br J Hosp Med (Lond). 2015 Mar;76(3):154-8. doi:10.12968/hmed.2015.76.3.154; Grunewald J, Eklund A. Sex-specific manifestations of Löfgren's syndrome. Am J Respir Crit Care Med. 2007 Jan 1;175(1):40-4. Epub 2006 Oct 5.; Razdan PS, Buteau D, Pollock NW. A case of Löfgren's syndrome confused with decompression sickness. Diving Hyperb Med. 2019 Dec 20;49(4):306-10. doi:10.28920/dhm49.4.306-310; Glennas A, Kvien TK, Melby K, et al. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol. 1995 Jan;34(1):45-50.; Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of Sarcoidosis 1946–2013: A Population-Based Study. Mayo Clin Proc. 2016 Feb;91(2):183-8. doi:10.1016/j.mayocp.2015.10.024. Epub 2015 Dec 22.; Tejera Segura B, Holgado S, Mateo L, et al. Löfgren syndrome: a study of 80 cases. Med Clin (Barc). 2014 Aug 19;143(4):166-9. doi:10.1016/j.medcli.2014.02.029. Epub 2014 May 22.; Mana J, Gomez-Vaquero C, Montero A, et al. Löfgren’s syndrome revisited: a study of 186 patients. Am J Med. 1999 Sep;107(3):240-5.; Judson MA. Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep. 2014 Oct 1;6:89. doi:10.12703/P6-89. eCollection 2014.; Govender P, Berman JS. The Diagnosis of Sarcoidosis. Clin Chest Med. 2015 Dec;36(4): 585-602. doi:10.1016/j.ccm.2015.08.003. Epub 2015; https://mrj.ima-press.net/mrj/article/view/1013

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1013
https://doi.org/10.14412/1996-7012-2020-2-35-40